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Abstract
Toll-like receptor (TLR)-8 agonists activate adaptive immune responses by inducing robust
production of T helper 1-polarizing cytokines, suggesting that TLR8-active compounds may be
promising candidate adjuvants. We synthesized and evaluated hitherto unexplored furo[2,3-
c]quinolines and its regioisomeric furo[3,2-c]quinolines, derived via a tandem, one-pot
Sonogashira coupling and intramolecular 5 endo-dig cyclization strategy, in a panel of primary
screens. We observed a pure TLR8 agonistic activity profile in select furo[2,3-c]quinolines, with
maximal potency conferred by a C2-butyl group (EC50: 1.6 µM); shorter, longer, or substituted
homologues, as well as compounds bearing C1 substitutions were inactive, which was rationalized
by docking studies using the recently-described crystal structure of human TLR8. The best-in-
class compound displayed prominent proinflammatory cytokine induction (including
interleukin-12 and interleukin-18), but was bereft of interferon-α inducing properties, confirming
its high selectivity for human TLR8.
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Introduction
Vaccines have played an indispensable role in the dramatic improvement in public health
witnessed in modern times, particularly in the prevention of mortality and morbidity
attributable to infectious diseases.1 While the successes of active immunization beginning
with Jenner’s smallpox vaccine in 1796 are numerous and extraordinary, our failure to
develop effective vaccines against diseases such as the human immunodeficiency virus
(HIV), tuberculosis, and malaria have served to highlight deficiencies and shortcomings of
the state-of-the-art in contemporary vaccine technology, catalyzing a renaissance in rational
vaccine design and development.2,3
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A component that is being increasingly recognized as pivotal in the design of effective
vaccines is the incorporation of appropriate immune potentiators (also termed adjuvants)
along with the antigen. Adjuvants initiate early innate immune responses which
subsequently lead to the induction of robust and long-lasting adaptive immune responses.4
Aluminum salts (primarily phosphate and hydroxide), discovered by Glenny and
coworkers,5 have been the only adjuvants in clinical use until the recent approval of 3-O-
desacyl-4'-monophosphoryl lipid A (MPL) by the FDA.6 Aluminum salts are weak
adjuvants for antibody induction, promoting a T helper 2 (Th2)-skewed, rather than a Th1
response;7,8 they are virtually ineffective at inducing cytotoxic T lymphocyte or mucosal
immunoglobulin A (IgA) antibody responses, and additionally, also appear to promote the
induction of IgE isotype switching, which has been associated with allergic reactions in
some subjects.7,8
Innate immune afferent signals activated by vaccine adjuvants include those originating
from Toll-like receptors (TLRs), as well as retinoic acid-inducible gene 1 (RIG-I)-like
receptors9 and nucleotide oligomerization domain (NOD)-like receptors (NLRs).10,11 There
are 10 functional TLRs encoded in the human genome, which are trans-membrane proteins
with an extracellular domain having leucine-rich repeats (LRR) and a cytosolic domain
called the Toll/IL-1 receptor (TIR) domain.12 The ligands for these receptors are highly
conserved molecules such as lipopolysaccharides (LPS) (recognized by TLR4), lipopeptides
(TLR2 in combination with TLR1 or TLR6), flagellin (TLR5), single stranded RNA (TLR7
and TLR8), double stranded RNA (TLR3), CpG motif-containing DNA (recognized by
TLR9), and profilin present on uropathogenic bacteria (TLR11).12 TLR1, −2, −4, −5, and −6
recognize extracellular stimuli, while TLR3, −7, −8 and −9 function within the
endolysosomal compartment.12 The activation of TLRs by their cognate ligands leads to
production of inflammatory cytokines, and up-regulation of major histocompatibility
complex (MHC) molecules and co-stimulatory signals in antigen-presenting cells (APCs) as
well as activating natural killer (NK) cells (innate immune response), which leads to the
priming and amplification of T-, and B-cell effector functions (adaptive immune
responses).13–16
We have recently embarked on a systematic exploration17,18 of a variety of TLR agonists
with a view to identifying safe and potent vaccine adjuvants. The chemotypes that we have
explored thus far include agonists of TLR2,19–21 TLR7,22–26 TLR8,27,28 NOD1,29 as well as
C-C chemokine receptor type 1.30
Our efforts are currently focused on evaluating small molecule agonists of TLR8 as potential
vaccine adjuvants. TLR8 is expressed in myeloid DCs, monocytes, and monocyte-derived
dendritic cells, and engagement of TLR8 agonists induces a dominant proinflammatory
cytokine profile including tumor necrosis factor-α (TNF-α), interleukin-12 (IL-12), and
IL-18.31 The prominent nuclear factor-κB (NF-κB)- and c-Jun N-terminal kinase-mediated
stimulatory effects of TLR8-agonists on APCs 32,33 leads to robust Th1-type responses.34
Unlike TLR2, −4, or −7 agonists, TLR8 agonists appear unique in markedly upregulating
the production of Th1-polarizing cytokines TNF-α and IL-12 from neonatal APCs,34
suggesting that TLR8 agonists may be useful as adjuvants for enhancing immune responses
in newborns.
Furthermore, human T-regulatory cells (Tregs), classified immunophenotypically as
naturally occurring (CD4+CD25+Foxp3+) or induced (CD4+CD25high), down-regulate and
suppress a broad array of immune responses, including the non-specific suppression of both
CD4+ and CD8+ T-cells via cell-cell contact and via production of immunosuppressive
cytokines such as IL-10 and transforming growth factor–β (TGF-β).35–41 Tregs express
abundant TLR8 mRNA, and TLR8 agonists have been shown to reverse Treg function via a
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TLR8-MyD88 (myeloid differentiation factor 88)-IRAK4 (IL-1-receptor-associated kinase
4) signaling pathway.42 Engagement and activation of TLR8 are, therefore, strongly
associated with enhanced adaptive immune responses.
A prerequisite for the careful evaluation of TLR8 activators as potential adjuvants for
neonatal vaccines is the availability of pure TLR8 agonists with negligible TLR7 activity
and, other than the 2,3-diamino-furo[2,3-c]pyridine class of compounds recently described
by us,28 all other known agonists of TLR8 such as the imidazoquinolines (for instance,
1),25,43 thiazoloquinolines (CL075, 2),27,44–47 and a 2-aminobenzazepine derivative
(VTX-2337, 3),48 all display mixed TLR7/TLR8-agonism, with the sole exception of
VTX-294,49 whose complete structure has not been reported. The structures of these mixed
agonists are shown in Fig. 1. The 2,3-diamino-furo[2,3-c]pyridines are atypical and
noncanonical in that although they activate TLR8-dependent NF-κB signaling, they are
devoid of proinflammatory cytokine inducing activities.28
Driven by our desire to identify pure TLR8 agonists also capable of inducing IL-12 and
IL-18, and drawing from our earlier work in delineating structure-activity relationships
(SAR) in the furo[2,3-c]pyridines, we began exploring a variety of fused heterocyclic core
structures. Our continuing investigations have led to the discovery of pure TLR8-agonistic
activity associated with strong interferon-γ (IFN-γ), IL-12 and IL-18 inducing activities in a
series of furo[2,3-c]quinolines. The 4-amino-furo[2,3-c]quinoline chemotype is
unprecedented in the literature, and the activity profile of this class of compounds, examined
by a range of secondary screens in human ex vivo blood models, including transcriptomal
profiling, confirm pure TLR8 agonism with no detectable signatures of TLR7 activity,
allowing for the first time a clear path toward the evaluation of such compounds as potential
adjuvants for vaccines.
Results and Discussion
Our recent work on the 2,3-diamino-furo[2,3-c]pyridines, which displayed TLR8-dependent
NF-κB signaling but dissociated from downstream cytokine induction led us to consider
benzologues of the furo[2,3-c]pyridines. The 4-amino-furo[2,3-c]quinoline chemotype is
hitherto not described in the literature, and presented a good starting point since its scaffold
closely resembles known TLR7/8-active ligands. We envisioned that the furo[2,3-
c]quinoline and its regioisomeric core structures could be derived via one-pot Sonogashira
coupling of alkynes to either 4-iodoquinolin-3-ol (Scheme 1), or 3-iodoquinolin-4-ol
(Scheme 2), followed by a tandem, tethered nucleophile-assisted, intramolecular 5 endo-dig
cyclization.50 Electrophilic iodination of commercially-available 3- and 4-hydroxyquinoline
proceeded uneventfully using reported methods (Schemes 1 and 2, respectively).51 One-pot
Sonogashira coupling with a variety of alkynes, followed by 5-endo-dig cyclization yielded
compounds the 2-substituted furo[2,3-c]quinolines 6a–y (Scheme 1) and the regioisomeric
furo[3,2-c]quinolines 11a–c (Scheme 2) in good yields. The target compounds 8a–y and
13a–c bearing 4-amino groups were obtained using conventional procedures described
previously.23,27,44 Compounds 8a–y and 13a–c were screened in a panel of reporter gene
assays for human TLR2/3/4/5/7/8/9 and NOD1/2 modulatory activities. We were fortunate
that a distinct activity profile was observed in the very first set of compounds that were
synthesized. Compounds 8b–f showed pure TLR8 agonistic activity with maximal potency
exhibited by 8d with a C2-butyl group (EC50: 1.6 µM, Fig. 2); shorter (8b, 8c) and longer
(8e, 8f) homologues displayed lower agonistic potencies with the shortest analogue 8a being
inactive (Fig. 2). The dose-response profiles show characteristic biphasic responses (dose-
dependent activation, followed by apparent suppression of NF-κB translocation, Fig. 2) as
we had previously observed in several chemotypes.23,28,52 We verified that the apparent
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suppression was not due to cytotoxicity using LDH release and mitochondrial redox-based
assays as described earlier by us.53,54
The SAR pattern with maximal activity conferred by a C2-butyl group is virtually identical
to that found in TLR7-active imidazoquinolines,23 and the TLR8/7-agonistic
thiazoloquinolines,27 but unlike the thiazoloquinolines,27 8d was devoid of TLR7-
stimulatory activities in primary screens (Fig. 2). The exquisite selectivity for TLR8 was
confirmed in secondary screens using ex vivo whole human blood and PBMC models.17 We
had earlier shown that proinflammatory cytokine induction (TNF-α, IL-1β, IL-6 and IL-8) is
a consequence of TLR8 activation.18 Importantly, Th1-biasing IL-12 and IL-18 induction is
also TLR8-dependent, while IFN-α production is TLR7-mediated.24,52 We therefore
examined cytokine and interferon induction profiles of 8d, employing the thiazoloquinoline
2 as a reference compound. Unlike the 2,3-diamino-furo[2,3-c]pyridines,28 8d was observed
to induce TNF-α, IL-1β, IL-6 and IL-8 in a dose-dependent manner, albeit with a lower
potency than 2 (Fig. 3). Compound 8d induced IL-12 and IL-18, but was bereft of IFN-α-
inducing properties (Fig. 4). The selectivity of 8d for TLR8 was also reflected in the absence
of natural killer lymphocyte activation17,18 in human whole blood models as assessed by
cluster of differentiation 69 (CD69) expression (Fig. 5), which we had previously shown to
be TLR7-dependent.17,18 Consistent with the above findings, transcriptomal profiling
experiments showed strong induction of proinflammatory cytokine transcripts (including
IL-12 and IL-18) by both 2 and 8d, but IFN-α transcription was induced only by 2, owing to
its dual TLR8/7 agonistic activity (Table 1). These data collectively confirm the selectivity
of 8d for human TLR8.
Given that 8d represents an optimized compound in a uniquely TLR8-specific chemotype,
we also profiled cytokine- and chemokine-inducing properties using a 41-analyte,
multiplexed assay, comparing 8d to a variety of TLR agonists. We found that of the 41
analytes analyzed, whereas both 8d and 2 induced granulocyte colony-stimulating factor (G-
CSF), growth-related oncogene (GRO), and macrophage inflammatory proteins 1-α and -β
(MIP-1α, MIP-1β), a highly potent, pure TLR7-agonistic imidazoquinoline (1-benzyl-2-
butyl-1H–imidazo[4,5-c]quinolin-4-amine) that we had identified in our earlier SAR
studies23 did not (Fig. 6), indicating that this set of analytes could be useful in distinguishing
TLR8-specific responses.
Distinct hints that the SAR in the 2-substituted furo[2,3-c]quinolines was much more
stringent compared to the thiazoloquinolines27 was evident right from the outset. C2
substituents with branched alkyl groups (8g–i) abrogated activity, and analogues with
cycloaliphatic (8j–8m) or aromatic (8n, 8o) substituents were inactive, pointing to
intolerance of steric bulk at the putative binding site(s). Since the crystal structure of TLR8
was not available at the time, we forged on, surmising that the introduction of polar H-bond
donors (or acceptors) on the C2 alkyl group may help us better understand binding site
interactions. We therefore examined a number of analogues bearing hydroxyl groups at
various positions along the C2-alkyl chain (8p–8v), compounds with C2 substituents
terminating with a primary amine (8x, 8y), as well as an analogue with an ether (H-bond
acceptor) incorporated in the alkyl group (8w), but none of these compounds were active in
any of our primary screens.
Mindful of our earlier observation that regioisomerism in the imidazoquinolines resulted in a
switch from agonistic to antagonistic activities,22,55 we also synthesized key regioisomeric
furo[3,2-c]quinolines, 13a–c (Scheme 2); these compounds were quiescent, displaying
neither stimulatory nor inhibitory activity in primary screens. Given the fastidious structural
requirements at the C2 position, we next synthesized a furo[2,3-c]isoquinoline with a C2-
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butyl substituent (18, Scheme 3) in an order to explore chemical space beyond the fused-
quinoline chemotypes, but were disappointed in that 18, too, was inactive.
Reverting, therefore, to the C2-butyl furo[2,3-c]quinoline, we interrogated the effect of
introducing substituents at the C1 position. We were, in particular, desirous of evaluating a
C1-benzyl substituent, for this strategy had previously yielded highly potent, TLR7-selective
agonists in the imidazoquinoline series.23 Electrophilic bromination of 7d furnished
precursor 19 in good yield (Scheme 4) which was carried forward to obtain both the 1-
bromo- and 1-benzyl-substituted analogues 21 and 24, respectively (Scheme 4). Both
analogues were found to be inactive.
As mentioned earlier, the 2,3-diamino-furo[2,3-c]pyridine class of compounds recently
described by us28 activate TLR8 but do not result in downstream cytokine production,
suggesting an apparent dissociation between receptor occupancy, and signal transduction
events leading to cytokine production, and it was of interest to compare SAR that we had
gleaned from the furo[2,3-c]quinolines with select analogues of the 4-amino, C2-alkyl
furo[2,3-c]pyridine series. Two such compounds (28a, 28b) were therefore synthesized
(Scheme 5). Both these analogues retained TLR8-selective agonistic activities, but were
substantially weaker (EC50: 24.4 µM and 46.2 µM, respectively) than 8d (EC50: 1.6 µM).
Although at first glance our attempts at exploring SAR in the furo[2,3-c]quinolines had
yielded a large number of inactive compounds, we are delighted in no small measure that we
have finally arrived at pure TLR8 agonists that induce the expected complement of TLR8-
mediated, Th1-biasing cytokine mediators, but are devoid of TLR7-dependent IFN-α-
inducing properties. Just as we were concluding our studies on the furo[2,3-c]quinolines,
crystal structures of hTLR8 complexed with mixed TLR7/TLR8-agonistic
imidazoquinolines and thiazoloquinolines were reported,56 allowing us to rationalize our
experimentally-determined SAR on the pure TLR8-agonistic furo[2,3-c]quinolines. The
crystal structure of human TLR8 in complex with 2 (PDB ID: 3W3K)56 was used for
docking studies. We employed induced-fit methods57,58 in which the receptor sites were
allowed conformational and torsional flexibility to simulate realistic ligand-receptor
interactions to account for conformational changes in the binding site residues. 2 as well as
8d occupy the same binding pocket formed by both the TLR8 protomers (Fig. 7A – B), with
the binding geometry of these compounds and interacting residues being virtually identical
(Fig. 7C – D). Strong ionic H-bonds (salt bridges) are observed between the C4-amine of
both 2 and 8d with Asp543 of protomer B, with additional stabilization derived from a H-
bond between Thr574 (protomer B) and either the N3 atom of the thiazole ring of 2, or the
oxygen atom of the furanyl ring of 8d. π-π interactions of the quinoline moiety of 2 and 8d
(Phe405/Tyr353), as well as hydrophobic interactions of the C2-alkyl group (Phe346/Ile403/
Gly376) occur exclusively with residues in protomer A (Fig. 7C – D). All of these
interactions appear indispensable. The butyl group of 8d allows for excellent nonpolar and
van der Waals contacts in the rather shallow hydrophobic cavity, and homologues with
increasing C2-chain length (8e–8f) dock poorly with kinked and sterically unfavorable
conformations of the alkyl group. Analogues with cycloaliphatic (8j–8m) and aromatic
substituents (8n, 8o) do not fit in the hydrophobic pocket at all, leading to unrealistic docked
conformations (not shown). The cavity is lined entirely with side-chains of hydrophobic
residues, explaining why even length-optimized analogues bearing polar groups at the C2
position such as 8r, 8u and 8v do not display TLR8 agonism. The feeble activity of the
furopyridine compounds 28a and 28b imply significant contributions in binding free
energies by π-π interactions of the quinoline moiety with Tyr353 and Phe405. The
imposition of additional steric bulk at C1 (compound 24) is not tolerated in the cleft
bounded by Phe261 and Ser352 (Fig. 7D). Not only is pivotal ionic H-bond between the C4-
amine of regioisomeric furo[3,2-c]quinoline 13b and Asp543 weakened (3.8 Å), the
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additional H-bond between the oxygen atom of the furan ring and Thr574 is lost, forcing
13b to bind to TLR8 in an inverted fashion, with the C2-alkyl group facing the entrance to
the binding site (Fig. 7E). Highly unfavorable H-bonds are also seen in the isoquinoline
analogue 18, especially with the loss of H-bonding of the furanyl oxygen (Fig. 7F).
In conclusion, an exploration of furo[2,3-c]quinolines have yielded pure TLR8 agonists,
which are expected to possess strong Th1-biasing adjuvantic properties as evidenced by
prominent IL-12 and IL-18 induction profiles, and are without IFN-α inducing properties,
confirming its exquisite selectivity for human TLR8. The recently published atomic
structure of human TLR8 has permitted a careful evaluation of SAR in this hitherto
uncharacterized chemotype, and provides clear directions toward rational, structure-based
ligand design. Immunization studies employing neonatal animal models are being planned
with a view to comparing adjuvanticity of agonists with pure TLR7 and TLR8 agonistic
properties vis-à-vis compounds with dual TLR7/8-stimulatory activities.
Experimental Section
Chemistry
All of the solvents and reagents used were obtained commercially and used as such unless
noted otherwise. Moisture- or air-sensitive reactions were conducted under nitrogen
atmosphere in oven-dried (120 °C) glass apparatus. The solvents were removed under
reduced pressure using standard rotary evaporators. Flash column chromatography was
carried out using RediSep Rf ‘Gold’ high performance silica columns on CombiFlash Rf
instrument unless otherwise mentioned, while thin-layer chromatography was carried out on
silica gel (200 µm) CCM pre-coated aluminum sheets. Purity for all final compounds was
confirmed to be greater than 97% by LC-MS using a Zorbax Eclipse Plus 4.6 mm × 150
mm, 5 µm analytical reverse phase C18 column with H2O-isopropanol or H2O-CH3CN
gradients and an Agilent ESI-QTOF mass spectrometer (mass accuracy of 3 ppm) operating
in the positive ion (or negative ion, as appropriate) acquisition mode.
Synthesis of 4-iodoquinolin-3-ol (5)
In an oven dried round bottom flask equipped with a stirring bar was placed 3-hydroxy
quinoline (1.0 g, 6.89 mmol) in 2N NaOH (20 mL). To this mixture a solution of iodine
(8.27 mmol) in 20% of aqueous potassium iodide (20 mL) was added drop-wise and stirred
for 3 h at room temperature. The mixture was then acidified with acetic acid, and the
precipitate was filtered and washed with water. After drying under vacuum, 1.50 g of 5 was
obtained, which was used without purification. 1H NMR (500 MHz, DMSO) δ 11.19 (s,
1H), 8.50 (s, 1H), 7.98 – 7.85 (m, 2H), 7.65 – 7.60 (m, 1H), 7.60 – 7.55 (m, 1H). 13C NMR
(126 MHz, DMSO) δ 152.2, 142.6, 141.3, 130.9, 129.9, 129.2, 128.5, 126.6, 94.5. MS (ESI)
calculated for C9H6INO, m/z 270.95, found 271.96 (M+H)+.
General procedure for Sonogashira reaction
To a stirred solution of 4-iodoquinolin-3-ol in acetonitrile:triethylamine (2:1) were added the
appropriate alkyne (0.553 mmol), Pd(PPh3)4 (0.018 mmol) and CuI (0.018 mmol). The
resulting reaction mixture was stirred at 70°C under nitrogen atmosphere for 12 h. After
completion of reaction (monitored by TLC), the reaction mixture was diluted with water and
extracted with ethylacetate (3 × 10 mL). The combined organic layer was dried over
Na2SO4 and concentrated under reduced pressure, crude material was purified by flash
chromatography using CH2Cl2:MeOH as an eluent.
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Yellow solid (60 mg, 78%). 1H NMR (500 MHz, CDCl3) δ 9.08 (s, 1H), 8.20 (d, J = 8.2 Hz,
1H), 8.07 (dd, J = 8.1, 1.2 Hz, 1H), 7.67 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 7.60 (ddd, J = 8.1,
7.0, 1.2 Hz, 1H), 6.91 (d, J = 0.8 Hz, 1H), 2.91 – 2.86 (m, 2H), 1.91 – 1.82 (m, 2H), 1.06 (t,
J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 163.0, 148.8, 144.3, 136.3, 131.4, 130.1,
127.3, 126.5, 123.7, 123.2, 101.1, 30.8, 21.2, 13.9. MS (ESI) calculated for C14H13NO, m/z
211.10, found 212.11 (M+H)+.
2-butylfuro[2,3-c]quinoline (6d)
Yellow solid (70 mg, 83%). 1H NMR (500 MHz, CDCl3) δ 9.08 (d, J = 0.5 Hz, 1H), 8.19
(dd, J = 8.4, 0.5 Hz, 1H), 8.09 – 8.05 (m, 1H), 7.66 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 7.60
(ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 6.90 (d, J = 0.8 Hz, 1H), 2.92 (t, 2H), 1.82 (ddd, J = 15.2,
8.5, 6.7 Hz, 2H), 1.51 – 1.42 (m, 2H), 0.99 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)
δ 163.2, 148.8, 144.3, 136.4, 131.4, 130.1, 127.3, 126.5, 123.7, 123.2, 101.0, 29.9, 28.5,
22.4, 13.9. MS (ESI) calculated for C15H15NO, m/z : 225.11, found 226.13 (M+H)+.
2-pentylfuro[2,3-c]quinoline (6e)
White solid (70 mg, 79%). 1H NMR (500 MHz, CDCl3) δ 9.08 (d, J = 0.7 Hz, 1H), 8.20 (dd,
J = 8.4, 0.6 Hz, 1H), 8.07 (ddd, J = 8.1, 1.5, 0.6 Hz, 1H), 7.66 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H),
7.60 (ddd, J = 8.1, 6.9, 1.3 Hz, 1H), 6.91 – 6.90 (m, 1H), 2.91 (t, J = 7.2 Hz, 2H), 1.88 –
1.80 (m, 2H), 1.46 – 1.35 (m, 4H), 0.93 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ
163.3, 148.8, 144.3, 136.4, 131.4, 130.1, 127.4, 126.5, 123.7, 123.2, 101.0, 31.5, 28.8, 27.5,
22.5, 14.1. MS (ESI) calculated for C16H17NO, m/z : 239.13, found 240.14 (M+H)+.
2-hexylfuro[2,3-c]quinoline (6f)
White solid (70 mg, 75%). 1H NMR (500 MHz, CDCl3) δ 9.08 (s, 1H), 8.20 (t, J = 8.3 Hz,
1H), 8.07 (dd, J = 8.1, 1.1 Hz, 1H), 7.66 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 7.60 (ddd, 1H), 6.90
(d, J = 0.6 Hz, 1H), 2.91 (t, J = 7.6 Hz, 2H), 1.87 – 1.79 (m, 2H), 1.50 – 1.40 (m, 2H), 1.39 –
1.28 (m, 4H), 0.90 (t, J = 8.2, 5.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 163.2, 148.8,
144.3, 136.3, 131.4, 130.1, 127.3, 126.5, 123.7, 123.2, 101.0, 31.7, 29.0, 28.9, 27.8, 22.7,
14.2. MS (ESI) calculated for C17H19NO, m/z : 253.15, found 254.16 (M+H)+.
2-isobutylfuro[2,3-c]quinoline (6g)
Liquid (120 mg, 72%). 1H NMR (500 MHz, CDCl3) δ 9.12 (s, 1H), 8.25 (d, J = 8.2 Hz, 1H),
8.08 (d, J = 7.9 Hz, 1H), 7.69 – 7.64 (m, 1H), 7.63 – 7.58 (m, 1H), 6.91 (s, 1H), 2.79 (dd, J =
7.1, 0.5 Hz, 2H), 2.20 (dp, J = 13.6, 6.8 Hz, 1H), 1.03 (d, J = 6.7 Hz, 6H). 13C NMR (126
MHz, CDCl3) δ 162.4, 144.3, 136.4, 131.5, 130.2, 127.4, 126.6, 123.7, 102.0, 38.0, 28.1,
22.6. MS (ESI) calculated for C15H15NO, m/z : 225.12, found 226.13 (M+H)+.
2-(tert-butyl)furo[2,3-c]quinoline (6h)
White solid (69 mg, 83%). 1H NMR (500 MHz, CDCl3) δ 9.11 (s, 1H), 8.20 (d, J = 8.3 Hz,
1H), 8.08 (d, J = 7.9 Hz, 1H), 7.69 – 7.64 (m, 1H), 7.59 (t, J = 7.4 Hz, 1H), 6.89 (s, 1H),
1.47 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 170.7, 148.8, 144.3, 136.4, 131.2, 130.1, 127.3,
126.5, 123.6, 123.4, 98.2, 33.6, 29.1. MS (ESI) calculated for C15H15NO, m/z : 225.12,
found 226.14 (M+H)+.
2-isopentylfuro[2,3-c]quinoline (6i)
Solid (65 mg, 74%). 1H NMR (500 MHz, CDCl3) δ 9.10 (s, 1H), 8.21 (d, J = 8.3 Hz, 1H),
8.07 (d, J = 7.9 Hz, 1H), 7.70 – 7.63 (m, 1H), 7.59 (t, 1H), 6.90 (s, 1H), 2.91 (t, 2H), 1.79 –
1.64 (m, 3H), 0.99 (d, J = 6.4 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 163.4, 148.8, 144.3,
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136.3, 131.4, 130.2, 127.3, 126.5, 123.7, 123.2, 100.9, 36.7, 27.8, 26.8, 22.5. MS (ESI)
calculated for C16H17NO, m/z : 239.13, found 240.14 (M+H)+.
2-cyclopropylfuro[2,3-c]quinoline (6j)
Solid (60 mg, 78%). 1H NMR (500 MHz, CDCl3) δ 9.02 (d, J = 0.7 Hz, 1H), 8.17 (dd, J =
8.4, 0.6 Hz, 1H), 8.04 (ddd, J = 8.1, 1.5, 0.6 Hz, 1H), 7.66 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H),
7.58 (ddd, J = 8.1, 6.9, 1.2 Hz, 1H), 6.89 – 6.85 (m, 1H), 2.21 – 2.14 (m, 1H), 1.12 (dqd, J =
6.0, 2.4, 1.2 Hz, 4H). 13C NMR (126 MHz, CDCl3) δ 164.0, 148.3, 144.4, 136.0, 131.7,
130.1, 127.4, 126.4, 123.7, 123.0, 99.4, 10.1, 8.5. MS (ESI) calculated for C14H11NO, m/z :
209.10, found 210.10 (M+H)+.
2-cyclopentylfuro[2,3-c]quinoline (6k)
White solid (72 mg, 82%). 1H NMR (500 MHz, CDCl3) δ 9.08 (s, 1H), 8.20 (d, J = 8.3 Hz,
1H), 8.07 (d, J = 7.7 Hz, 1H), 7.70 – 7.64 (m, 1H), 7.59 (t, J = 11.0, 3.8 Hz, 1H), 6.91 (s,
1H), 3.41 – 3.31 (m, 1H), 2.23 – 2.13 (m, 2H), 1.95 – 1.81 (m, 4H), 1.81 – 1.69 (m, 2H). 13C
NMR (126 MHz, CDCl3) δ 166.8, 144.3, 136.4, 131.3, 130.1, 127.3, 126.5, 123.7, 123.2,
99.6, 39.4, 32.1, 25.6. MS (ESI) calculated for C16H15NO, m/z : 237.11, found 238.13 (M
+H)+.
2-(cyclopentylmethyl)furo[2,3-c]quinoline (6l)
Solid (71 mg, 757%). 1H NMR (500 MHz, CDCl3) δ 9.10 (s, 1H), 8.22 (d, J = 8.2 Hz, 1H),
8.08 (d, J = 7.9 Hz, 1H), 7.67 (t, J = 7.0 Hz, 1H), 7.60 (t, 1H), 6.91 (s, 1H), 2.91 (d, J = 7.4
Hz, 2H), 2.38 (dt, J = 15.4, 7.8 Hz, 1H), 1.87 (m, 2H), 1.74 – 1.65 (m, 2H), 1.64 – 1.57 (m,
2H), 1.32 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 163.0, 144.3, 136.4, 131.5, 130.2, 127.4,
126.5, 123.7, 101.5, 38.9, 34.9, 32.7, 25.2. MS (ESI) calculated for C17H17NO, m/z :
251.13, found 252.14 (M+H)+.
2-(cyclohexylmethyl)furo[2,3-c]quinoline (6m)
Solid (170 mg, 87%). 1H NMR (500 MHz, CDCl3) δ 9.10 (s, 1H), 8.21 (d, J = 8.3 Hz, 1H),
8.07 (d, J = 7.7 Hz, 1H), 7.72 – 7.63 (m, 1H), 7.59 (t, J = 7.4 Hz, 1H), 6.89 (s, 1H), 2.78 (d,
J = 6.9 Hz, 2H), 1.89 – 1.64 (m, 6H), 1.33 – 1.12 (m, 3H), 1.05 (qd, J = 12.4, 3.1 Hz,
2H). 13C NMR (126 MHz, CDCl3) δ 162.1, 148.8, 144.23, 136.4, 131.4, 130.1, 127.3,
126.5, 123.7, 123.2, 102.0, 37.3, 36.7, 33.3, 26.4, 26.2. MS (ESI) calculated for C18H19NO,
m/z : 265.15, found 266.16 (M+H)+.
2-phenylfuro[2,3-c]quinoline (6n)
White solid (65 mg, 72%). 1H NMR (500 MHz, CDCl3) δ 9.20 (d, 1H), 8.23 (dd, J = 8.3, 0.7
Hz, 1H), 8.17 (ddd, J = 8.0, 1.5, 0.5 Hz, 1H), 8.01 – 7.97 (m, 2H), 7.71 (ddd, J = 8.4, 6.9, 1.6
Hz, 1H), 7.65 (ddd, J = 8.1, 7.0, 1.3 Hz, 1H), 7.55 – 7.50 (m, 3H), 7.47 – 7.43 (m, 1H). 13C
NMR (126 MHz, CDCl3) δ 158.8, 148.9, 144.5, 136.7, 131.6, 130.3, 129.8, 129.8, 129.2,
127.7, 126.9, 125.6, 123.7, 123.2, 99.9. MS (ESI) calculated for C17H11NO, m/z : 245.10,
found 246.10 (M+H)+.
furo[2,3-c]quinolin-2-ylmethanol (6p)
Solid (56 mg, 77%). 1H NMR (500 MHz, MeOD) δ 9.07 (s, 1H), 8.26 (dd, J = 8.0, 1.2 Hz,
1H), 8.12 (d, J = 8.2 Hz, 1H), 7.77 – 7.71 (m, 1H), 7.71 – 7.66 (m, 1H), 7.39 (s, 1H), 4.84 (s,
2H). 13C NMR (126 MHz, MeOD) δ 163.5, 150.2, 144.8, 137.2, 133.0, 129.7, 129.1, 128.3,
125.0, 124.6, 103.3, 58.1. MS (ESI) calculated for C12H9NO2, m/z : 199.10, found 200.07
(M+H)+.
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Solid (58 mg, 74%). 1H NMR (500 MHz, MeOD) δ 9.02 (s, 1H), 8.23 (dd, 1H), 8.10 (dd, J =
8.3, 0.5 Hz, 1H), 7.71 (ddd, J = 8.5, 7.0, 1.6 Hz, 1H), 7.67 (ddd, J = 8.1, 7.0, 1.3 Hz, 1H),
7.26 (d, J = 0.7 Hz, 1H), 4.01 (t, J = 6.4 Hz, 2H), 3.17 (td, J = 6.4, 0.6 Hz, 2H). 13C NMR
(126 MHz, MeOD) δ 162.9, 149.9, 144.7, 136.7, 133.6, 129.6, 128.9, 128.0, 125.1, 124.4,
103.5, 60.6, 33.1. MS (ESI) calculated for C13H11NO2, m/z : 213.08, found 214.09 (M+H)+.
4-(furo[2,3-c]quinolin-2-yl)butan-1-ol (6s)
Solid (68 mg, 77%). 1H NMR (500 MHz, MeOD) δ 8.99 (s, 1H), 8.22 – 8.18 (m, 1H), 8.09
(dd, J = 8.4, 0.6 Hz, 1H), 7.70 (ddd, J = 8.4, 6.9, 1.6 Hz, 1H), 7.65 (ddd, J = 8.1, 7.0, 1.3 Hz,
1H), 7.17 (d, J = 0.8 Hz, 1H), 3.63 (t, J = 6.4 Hz, 2H), 2.98 (t, 2H), 1.96 – 1.88 (m, 2H), 1.71
– 1.63 (m, 2H). 13C NMR (126 MHz, MeOD) δ 165.5, 149.8, 144.7, 136.6, 133.6, 129.5,
128.9, 128.0, 125.1, 124.3, 102.4, 62.4, 33.0, 29.2, 25.2. MS (ESI) calculated for
C15H15NO2, m/z : 241.11, found 242.12 (M+H)+.
2-(furo[2,3-c]quinolin-2-yl)propan-2-ol (6t)
White solid (60 mg, 72%). 1H NMR (500 MHz, MeOD) δ 9.07 (d, J = 0.6 Hz, 1H), 8.29 –
8.24 (m, 1H), 8.14 – 8.10 (m, 1H), 7.73 (ddd, J = 8.5, 7.0, 1.6 Hz, 1H), 7.68 (ddd, J = 8.1,
7.0, 1.3 Hz, 1H), 7.36 (d, J = 0.8 Hz, 1H), 1.72 (s, 6H). 13C NMR (126 MHz, MeOD) δ
169.7, 149.9, 144.8, 137.1, 133.0, 129.7, 129.0, 128.2, 125.0, 124.6, 100.6, 70.1, 29.1. MS
(ESI) calculated for C14H13NO2, m/z : 227.10, found 228.11 (M+H)+.
1-(furo[2,3-c]quinolin-2-yl)propan-2-ol (6v)
White solid (70 mg, 84%). 1H NMR (500 MHz, MeOD) δ 9.04 (d, J = 0.5 Hz, 1H), 8.27 –
8.23 (m, 1H), 8.11 (dd, J = 8.4, 0.6 Hz, 1H), 7.73 (ddd, J = 8.5, 7.0, 1.6 Hz, 1H), 7.68 (ddd, J
= 8.1, 7.0, 1.3 Hz, 1H), 7.28 (d, J = 0.7 Hz, 1H), 4.32 – 4.25 (m, 1H), 3.09 (d, J = 6.2 Hz,
2H), 1.31 (d, J = 6.2 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 163.0, 149.9, 144.6, 136.7,
133.7, 129.5, 129.0, 128.1, 125.1, 124.4, 104.0, 67.1, 39.2, 23.4. MS (ESI) calculated for
C14H13NO2, m/z : 227.10, found 228.11 (M+H)+.
2-(2-ethoxyethyl)furo[2,3-c]quinoline (6w)
Solid (70 mg, 77%). 1H NMR (500 MHz, CDCl3) δ 9.10 (s, 1H), 8.21 (d, J = 8.3 Hz, 1H),
8.08 (dd, J = 8.1, 1.1 Hz, 1H), 7.68 (ddd, J = 8.4, 7.0, 1.4 Hz, 1H), 7.63 – 7.59 (m, 1H), 7.02
(d, 1H), 3.87 (t, J = 6.6 Hz, 2H), 3.57 (q, J = 7.0 Hz, 2H), 3.20 (td, J = 6.6, 0.8 Hz, 2H), 1.23
(t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 160.1, 148.8, 144.3, 136.3, 131.4, 130.1,
127.3, 126.6, 123.7, 123.2, 102.3, 68.0, 66.7, 29.8, 15.3. MS (ESI) calculated for
C15H15NO2, m/z : 241.11, found 242.11 (M+H)+.
2-(furo[2,3-c]quinolin-2-ylmethyl)isoindoline-1,3-dione (6x)
White solid (33 mg, 61%). 1H NMR (500 MHz, DMSO) δ 9.20 (d, J = 0.5 Hz, 1H), 8.32 (d,
1H), 8.11 (dd, J = 8.3, 0.7 Hz, 1H), 7.96 (dd, J = 5.5, 3.0 Hz, 2H), 7.89 (dd, J = 5.5, 3.1 Hz,
2H), 7.75 – 7.64 (m, 3H), 5.11 (d, J = 0.4 Hz, 2H). 13C NMR (126 MHz, DMSO) δ 167.3,
155.6, 148.3, 143.7, 136.6, 134.8, 131.6, 130.1, 129.6, 127.7, 126.9, 124.1, 123.5, 122.6,
103.8, 34.9. MS (ESI) calculated for C20H12N2O3, m/z : 328.08, found 329.10 (M+H)+.
2-(2-(furo[2,3-c]quinolin-2-yl)ethyl)isoindoline-1,3-dione (6y)
White solid (65 mg, 77%). 1H NMR (500 MHz, DMSO) δ 9.13 (s, 1H), 8.23 (dd, J = 8.0, 1.4
Hz, 1H), 8.10 (d, J = 8.2 Hz, 1H), 7.90 – 7.79 (m, 4H), 7.73 – 7.68 (m, 1H), 7.68 – 7.63 (m,
1H), 7.44 (s, 1H), 4.03 (t, J = 6.9 Hz, 2H), 3.30 (t, J = 6.9 Hz, 2H). 13C NMR (126 MHz,
DMSO) δ 167.7, 158.9, 148.5, 143.7, 136.2, 134.5, 131.6, 130.4, 129.5, 127.5, 126.7, 124.0,
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123.2, 122.6, 103.1, 36.0, 27.3. MS (ESI) calculated for C21H14N2O3, m/z : 342.10, found
343.12 (M+H)+.
General procedure for N-Oxidation
To a stirred solution of substrate (0.53 mmol) in CHCl3 was added m-CPBA (1.06 mmol).
The resulting reaction mixture was stirred at r.t. for 4 h. After completion of reaction
(monitored by TLC), the reaction mixture was diluted with water and extracted with CH2Cl2
(3 × 10 mL). The combined organic layer was dried over Na2SO4, concentrated under
reduced pressure, and the crude material was purified by flash chromatography.
2-methylfuro[2,3-c]quinoline 5-oxide (7b)
White solid (80 mg, 74%). 1H NMR (500 MHz, CDCl3) δ 8.86 (s, 1H), 8.84 (dd, 1H), 8.08 –
8.03 (m, 1H), 7.76 – 7.68 (m, 2H), 6.87 (t, 1H), 2.59 (d, J = 1.0 Hz, 3H). 13C NMR (126
MHz, CDCl3) δ 159.7, 147.2, 138.8, 129.0, 128.6, 124.5, 124.3, 122.7, 121.0, 102.2, 14.5.
MS (ESI) calculated for C12H9NO2, m/z : 199.10, found 200.06 (M+H)+.
2-propylfuro[2,3-c]quinoline 5-oxide (7c)
White solid (78 mg, 72%). 1H NMR (500 MHz, CDCl3) δ 8.88 – 8.82 (m, 2H), 8.08 – 8.04
(m, 1H), 7.75 – 7.68 (m, 2H), 6.86 (dd, J = 1.7, 0.8 Hz, 1H), 2.88 – 2.83 (m, 2H), 1.88 –
1.79 (m, 2H), 1.05 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 163.7, 147.1, 138.8,
128.9, 128.5, 124.4, 124.2, 124.1, 122.8, 121.1, 101.4, 30.7, 21.1, 13.9. MS (ESI) calculated
for C14H13NO2, m/z : 227.10, found 228.10 (M+H)+.
2-butylfuro[2,3-c]quinoline 5-oxide (7d)
White solid (75 mg, 70%). 1H NMR (500 MHz, CDCl3) δ 8.86 (d, J = 0.5 Hz, 1H), 8.85 –
8.83 (m, 1H), 8.08 – 8.04 (m, 1H), 7.75 – 7.68 (m, 2H), 6.86 (d, J = 0.9 Hz, 1H), 2.90 – 2.86
(m, 2H), 1.82 – 1.76 (m, 2H), 1.46 (dq, J = 14.7, 7.4 Hz, 2H), 0.98 (t, J = 7.4 Hz, 3H). 13C
NMR (126 MHz, CDCl3) δ 164.0, 147.1, 138.7, 128.9, 128.5, 124.5, 124.2, 124.2, 122.8,
121.0, 101.3, 29.8, 28.5, 22.4, 13.9. MS (ESI) calculated for C15H15NO2, m/z : 241.11,
found 242.12 (M+H)+.
2-pentylfuro[2,3-c]quinoline 5-oxide (7e)
White solid (77 mg, 72%). 1H NMR (500 MHz, CDCl3) δ 8.87 – 8.86 (m, 1H), 8.86 – 8.83
(m, 1H), 8.09 – 8.05 (m, 1H), 7.76 – 7.68 (m, 2H), 6.86 (d, J = 0.8 Hz, 1H), 2.87 (t, J = 7.4
Hz, 2H), 1.84 – 1.78 (m, 2H), 1.40 (qd, J = 4.6, 1.7 Hz, 2H), 0.93 (t, J = 7.1 Hz, 3H). 13C
NMR (126 MHz, CDCl3) δ 164.0, 147.1, 138.7, 128.9, 128.5, 124.5, 124.2, 124.2, 122.8,
121.1, 101.3, 31.5, 28.8, 27.4, 22.5, 14.1. MS (ESI) calculated for C16H17NO2, m/z : 255.12,
found 256.14 (M+H)+.
2-hexylfuro[2,3-c]quinoline 5-oxide (7f)
White solid (105 mg 82%). 1H NMR (500 MHz, CDCl3) δ 8.86 (d, J = 0.5 Hz, 1H), 8.86 –
8.82 (m, 1H), 8.08 – 8.05 (m, 1H), 7.75 – 7.68 (m, 2H), 6.86 (d, J = 0.9 Hz, 1H), 2.87 (t, J =
7.3 Hz, 2H), 1.80 (dt, J = 15.2, 7.5 Hz, 2H), 1.47 – 1.39 (m, 2H), 1.36 – 1.30 (m, 4H), 0.90
(t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 164.0, 147.1, 138.8, 128.9, 128.5, 124.5,
124.2, 124.2, 122.8, 121.1, 101.3, 31.6, 29.0, 28.8, 27.7, 22.7, 14.2. MS (ESI) calculated for
C17H19NO2, m/z : 269.14, found 270.15 (M+H)+.
2-isobutylfuro[2,3-c]quinoline 5-oxide (7g)
Solid (100 mg, 78%). 1H NMR (500 MHz, CDCl3) δ 8.87 (s, 1H), 8.85 (dt, J = 7.2, 3.9 Hz,
1H), 8.09 – 8.06 (m, 1H), 7.76 – 7.69 (m, 2H), 6.88 (d, J = 0.7 Hz, 1H), 2.76 (dd, J = 7.1, 0.5
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Hz, 2H), 2.22 – 2.12 (m, 1H), 1.03 (d, J = 6.7 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ
163.0, 147.2, 138.8, 128.9, 128.5, 124.5, 124.3, 124.1, 122.8, 121.1, 102.3, 37.9, 28.0, 22.6.
MS (ESI) calculated for C15H15NO2, m/z : 241.11, found 242.13 (M+H)+.
2-(tert-butyl)furo[2,3-c]quinoline 5-oxide (7h)
White solid (72 mg, 68%). 1H NMR (500 MHz, CDCl3) δ 8.88 (d, J = 0.6 Hz, 1H), 8.85 (dd,
J = 7.8, 2.1 Hz, 1H), 8.09 – 8.06 (m, 1H), 7.75 – 7.69 (m, 2H), 6.85 (d, J = 0.9 Hz, 1H), 1.45
(s, 9H). 13C NMR (126 MHz, CDCl3) δ 171.5, 147.1, 138.7, 128.9, 128.5, 124.6, 124.2,
124.1, 123.0, 121.1, 98.6, 29.0. MS (ESI) calculated for C15H15NO2, m/z : 241.11, found
242.12 (M+H)+.
2-isopentylfuro[2,3-c]quinoline 5-oxide (7i)
Solid (60 mg, 77%). 1H NMR (500 MHz, MeOD) δ 9.13 (d, J = 0.5 Hz, 1H), 8.72 (dd, J =
8.1, 1.6 Hz, 1H), 8.37 – 8.34 (m, 1H), 7.90 – 7.83 (m, 2H), 7.28 (d, J = 0.8 Hz, 1H), 3.01 –
2.96 (m, 2H), 1.78 – 1.72 (m, 2H), 1.72 – 1.65 (m, 1H), 1.01 (d, J = 6.5 Hz, 6H). 13C NMR
(126 MHz, MeOD) δ 167.7, 147.9, 138.8, 130.6, 130.5, 128.7, 126.7, 126.0, 124.0, 120.8,
102.8, 37.6, 28.9, 27.5, 22.7. MS (ESI) calculated for C16H17NO2, m/z : 255.12, found
256.13 (M+H)+.
2-cyclopropylfuro[2,3-c]quinoline 5-oxide (7j)
Solid (40 mg 74%). 1H NMR (500 MHz, MeOD) δ 9.11 – 8.99 (m, 1H), 8.73 (t, J = 13.1 Hz,
1H), 8.36 – 8.30 (m, 1H), 7.96 – 7.78 (m, 2H), 7.24 (s, 1H), 2.35 – 2.24 (m, 1H), 1.27 – 1.16
(m, 2H), 1.15 – 1.09 (m, 2H). 13C NMR (126 MHz, MeOD) δ 168.84, 130.7, 130.3, 129.8,
129.3, 126.0, 125.1, 123.6, 120.7, 100.9, 10.6, 9.2. MS (ESI) calculated for C14H11NO2, m/
z : 225.10, found 226.09 (M+H)+.
2-cyclopentylfuro[2,3-c]quinoline 5-oxide (7k)
White solid (77 mg, 72%). 1H NMR (500 MHz, MeOD) δ 9.12 (d, J = 0.4 Hz, 1H), 8.71 (dd,
1H), 8.35 (dd, 1H), 7.89 – 7.81 (m, 2H), 7.29 (d, J = 0.7 Hz, 1H), 3.47 – 3.39 (m, 1H), 2.26
– 2.14 (m, 2H), 1.96 – 1.85 (m, 4H), 1.81 – 1.72 (m, 2H). 13C NMR (126 MHz, MeOD) δ
171.0, 147.9, 138.8, 130.6, 130.5, 128.7, 126.7, 126.0, 124.0, 120.8, 101.5, 40.5, 32.8, 26.4.
MS (ESI) calculated for C16H15NO2, m/z : 253.11, found 254.12 (M+H)+.
2-(cyclopentylmethyl)furo[2,3-c]quinoline 5-oxide (7l)
White solid (75 mg, 70%). 1H NMR (500 MHz, MeOD) δ 9.13 (s, 1H), 8.74 – 8.70 (m, 1H),
8.36 (dd, J = 7.5, 1.8 Hz, 1H), 7.91 – 7.82 (m, 2H), 7.29 (d, J = 0.5 Hz, 1H), 2.96 (d, J = 7.4
Hz, 2H), 2.44 – 2.37 (m, 1H), 1.93 – 1.85 (m, 2H), 1.75 – 1.67 (m, 2H), 1.65 – 1.58 (m, 2H),
1.40 – 1.32 (m, 2H). 13C NMR (126 MHz, MeOD) δ 167.2, 147.9, 138.8, 130.6, 130.5,
128.7, 126.7, 126.0, 124.0, 120.8, 103.3, 40.0, 35.5, 33.5, 26.0. MS (ESI) calculated for
C17H17NO2, m/z : 267.12, found 268.14 (M+H)+.
2-(cyclohexylmethyl)furo[2,3-c]quinoline 5-oxide (7m)
Solid (160 mg, 84%). 1H NMR (500 MHz, CDCl3) δ 8.87 (s, 1H), 8.84 (dd, 1H), 8.09 – 8.05
(m, 1H), 7.76 – 7.69 (m, 2H), 6.86 (d, J = 0.7 Hz, 1H), 2.76 (d, J = 6.8 Hz, 2H), 1.90 – 1.52
(m, 6H), 1.33 – 1.14 (m, 3H), 1.08 – 0.97 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 162.9,
147.2, 138.7, 128.9, 128.5, 124.5, 124.3, 123.7, 122.8, 121.0, 102.3, 37.3, 36.6, 33.3, 29.9,
26.4, 26.2. MS (ESI) calculated for C18H19NO2, m/z : 281.14, found 282.16 (M+H)+.
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White solid (73 mg, 68%). 1H NMR (500 MHz, CDCl3) δ 8.96 (d, J = 0.7 Hz, 1H), 8.89 –
8.85 (m, 1H), 8.17 (ddd, J = 3.2, 2.2, 0.5 Hz, 1H), 7.94 – 7.90 (m, 2H), 7.80 – 7.74 (m, 2H),
7.53 – 7.49 (m, 2H), 7.47 (d, J = 0.9 Hz, 1H), 7.46 – 7.42 (m, 1H). 13C NMR (126 MHz,
CDCl3) δ 159.6, 147.5, 139.1, 129.9, 129.3, 129.3, 129.2, 128.8, 125.3, 124.5, 124.4, 124.3,
122.9, 121.2, 100.2. MS (ESI) calculated for C17H11NO2, m/z : 261.08, found 262.09 (M
+H)+.
2-benzylfuro[2,3-c]quinoline 5-oxide (7o)
White solid (96 mg 90%). 1H NMR (500 MHz, CDCl3) δ 8.85 (d, J = 0.6 Hz, 1H), 8.83 (dd,
1H), 8.04 – 8.01 (m, 1H), 7.75 – 7.67 (m, 2H), 7.38 (ddd, J = 7.2, 4.4, 1.6 Hz, 2H), 7.35 –
7.30 (m, 3H), 6.82 (d, J = 0.9 Hz, 1H), 4.21 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 162.0,
147.5, 138.9, 136.1, 129.1, 129.1, 129.0, 128.6, 127.4, 124.5, 124.2, 123.8, 122.8, 121.1,
102.7, 35.3. MS (ESI) calculated for C18H13NO2, m/z : 275.10, found 276.11 (M+H)+.
2-(hydroxymethyl)furo[2,3-c]quinoline 5-oxide(7p)
Yellow solid (77 mg, 79%).1H NMR (500 MHz, MeOD) δ 9.15 (s, 1H), 8.72 (dd, J = 7.9,
1.8 Hz, 1H), 8.38 – 8.31 (m, 1H), 7.91 – 7.82 (m, 2H), 7.43 (d, J = 0.6 Hz, 1H), 4.82 (s,
2H). 13C NMR (126 MHz, MeOD) δ 165.1, 148.4, 139.0, 130.7, 130.7, 127.8, 127.0, 125.9,
124.2, 120.9, 103.9, 57.9. MS (ESI) calculated for C12H9NO3, m/z : 215.10, found 216.07
(M+H)+.
2-(2-hydroxyethyl)furo[2,3-c]quinoline 5-oxide (7q)
White solid (75 mg, 78%)1H NMR (500 MHz, MeOD) δ 9.09 (d, J = 0.5 Hz, 1H), 8.68 (dd,
1H), 8.31 – 8.27 (m, 1H), 7.88 – 7.78 (m, 2H), 7.29 (d, J = 0.8 Hz, 1H), 3.99 (t, J = 6.3 Hz,
2H), 3.15 (td, J = 6.3, 0.7 Hz, 2H). 13C NMR (126 MHz, MeOD) δ 164.6, 147.9, 138.8,
130.6, 130.5, 128.5, 126.7, 125.9, 123.9, 120.8, 104.1, 60.5, 33.1. MS (ESI) calculated for
C13H11NO3, m/z : 229.10, found 230.09 (M+H)+.
2-(3-hydroxypropyl)furo[2,3-c]quinoline 5-oxide (7r)
White solid (75 mg, 88%). 1H NMR (500 MHz, MeOD) δ 9.13 (s, 1H), 8.75 – 8.69 (m, 1H),
8.38 – 8.33 (m, 1H), 7.90 – 7.82 (m, 2H), 7.30 (d, J = 0.9 Hz, 1H), 3.69 (t, J = 6.2 Hz, 2H),
3.06 (t, 2H), 2.10 – 2.00 (m, 2H). 13C NMR (126 MHz, MeOD) δ 167.0, 148.0, 138.8,
130.6, 130.5, 128.7, 126.7, 126.0, 124.0, 120.8, 103.0, 61.8, 31.5, 26.0. MS (ESI) calculated
for C14H13NO3, m/z : 243.10, found 244.10 (M+H)+.
2-(4-hydroxybutyl)furo[2,3-c]quinoline 5-oxide (7s)
Solid (60 mg, 76%). 1H NMR (500 MHz, MeOD) δ 8.99 (s, 1H), 8.22 – 8.18 (m, 1H), 8.09
(dd, J = 8.4, 0.6 Hz, 1H), 7.70 (ddd, J = 8.4, 6.9, 1.6 Hz, 1H), 7.65 (ddd, J = 8.1, 7.0, 1.3 Hz,
1H), 7.17 (d, J = 0.8 Hz, 1H), 3.63 (t, J = 6.4 Hz, 2H), 2.98 (t, 2H), 1.96 – 1.88 (m, 2H), 1.71
– 1.63 (m, 2H). 13C NMR (126 MHz, MeOD) δ 165.5, 149.8, 144.7, 136.6, 133.6, 129.5,
128.9, 128.0, 125.1, 124.3, 102.4, 62.4, 33.0, 29.2, 25.2. MS (ESI) calculated for
C15H15NO3, m/z : 257.10, found 258.11 (M+H)+.
2-(2-hydroxypropan-2-yl)furo[2,3-c]quinoline 5-oxide (7t)
White solid (63 mg 74%). 1H NMR (500 MHz, MeOD) δ 9.17 (s, 1H), 8.73 (d, 1H), 8.38
(dd, 1H), 7.92 – 7.83 (m, 2H), 7.42 (d, 1H), 1.70 (s, 6H). 13C NMR (126 MHz, MeOD) δ
171.2, 148.0, 139.0, 130.8, 130.7, 127.9, 127.0, 126.0, 124.3, 120.9, 101.3, 70.0, 29.0. MS
(ESI) calculated for C14H13NO3, m/z : 243.10, found 244.10 (M+H)+.
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Solid (60 mg, 70%). 1H NMR (500 MHz, MeOD) δ 9.18 (s, 1H), 8.74 (dd, 1H), 8.40 (dd,
1H), 7.92 – 7.85 (m, 2H), 7.46 (s, 1H), 4.98 (dd, J = 8.5, 5.1 Hz, 1H), 1.91 – 1.85 (m, 2H),
1.84 – 1.78 (m, 1H), 1.02 (dd, J = 6.3, 3.0 Hz, 6H). 13C NMR (126 MHz, MeOD) δ 168.3,
148.1, 139.0, 130.7, 130.7, 127.9, 127.0, 126.0, 124.3, 120.9, 102.8, 66.9, 45.7, 25.7, 23.6,
22.3. MS (ESI) calculated for C16H17NO3, m/z : 271.12, found 272.12 (M+H)+.
2-(2-hydroxypropyl)furo[2,3-c]quinoline 5-oxide (7v)
Solid (65 mg, 81%). 1H NMR (500 MHz, MeOD) δ 9.04 (d, J = 0.6 Hz, 1H), 8.63 – 8.60 (m,
1H), 8.27 – 8.24 (m, 1H), 7.80 – 7.72 (m, 2H), 7.23 (d, J = 0.7 Hz, 1H), 4.20 – 4.11 (m, 1H),
2.97 (ddd, J = 3.9, 2.6, 0.5 Hz, 2H), 1.21 (d, J = 6.2 Hz, 3H). 13C NMR (126 MHz, MeOD)
δ 164.5, 148.0, 138.8, 130.6, 130.5, 128.59, 126.8, 126.0, 124.0, 120.8, 104.6, 67.0, 39.2,
23.4. MS (ESI) calculated for C14H13NO3, m/z : 243.10, found 244.10 (M+H)+.
2-(2-ethoxyethyl)furo[2,3-c]quinoline 5-oxide (7w)
Solid (30 mg, 70%). 1H NMR (500 MHz, MeOD) δ 9.15 (d, J = 0.7 Hz, 1H), 8.74 – 8.71 (m,
1H), 8.39 – 8.35 (m, 1H), 7.91 – 7.84 (m, 2H), 7.34 (d, J = 0.9 Hz, 1H), 3.89 (t, J = 6.3 Hz,
2H), 3.58 (q, J = 7.0 Hz, 2H), 3.24 – 3.21 (m, 2H), 1.19 (t, J = 7.0 Hz, 3H). 13C NMR (126
MHz, MeOD) δ 164.7, 147.9, 138.9, 130.6, 130.6, 128.6, 126.8, 126.0, 124.0, 120.8, 103.9,
68.6, 67.4, 30.4, 15.4. MS (ESI) calculated for C15H15NO3, m/z : 257.10, found 258.11 (M
+H)+.
2-((1,3-dioxoisoindolin-2-yl)methyl)furo[2,3-c]quinoline 5-oxide (7x)
Solid (33 mg, 61%). 1H NMR (500 MHz, DMSO) δ 9.22 (s, 1H), 8.63 – 8.59 (m, 1H), 8.41
– 8.36 (m, 1H), 7.97 – 7.93 (m, 2H), 7.91 – 7.87 (m, 2H), 7.83 – 7.76 (m, 2H), 7.67 (d, J =
0.7 Hz, 1H), 5.06 (s, 2H). 13C NMR (126 MHz, DMSO) δ 167.2, 155.4, 147.4, 138.5, 134.8,
131.6, 129.3, 128.6, 124.9, 124.1, 123.5, 122.4, 121.6, 120.0, 104.4, 34.7. MS (ESI)
calculated for C20H12N2O4, m/z : 344.08, found 345.09 (M+H)+.
2-(2-(1,3-dioxoisoindolin-2-yl)ethyl)furo[2,3-c]quinoline 5-oxide (7y)
Solid (65 mg, 77%). 1H NMR (500 MHz, MeOD) δ 8.92 (d, J = 0.7 Hz, 1H), 8.70 (dd, J =
8.2, 1.5 Hz, 1H), 8.21 – 8.17 (m, 1H), 7.84 – 7.77 (m, 4H), 7.77 – 7.73 (m, 2H), 7.19 (d, J =
0.8 Hz, 1H), 4.15 (t, J = 6.7 Hz, 2H), 3.35 (t, J = 7.1, 6.5 Hz, 2H). 13C NMR (126 MHz,
MeOD) δ 168.9, 161.8, 147.5, 138.4, 135.0, 134.9, 132.4, 130.0, 130.0, 127.3, 125.8, 125.3,
124.0, 123.9, 123.4, 120.5, 104.0, 36.6, 28.3. MS (ESI) calculated for C21H14N2O4, m/z :
358.10, found 359.11 (M+H)+.
General procedure for installation of the 4-amino group
To a stirred solution of N-oxide (0.414 mmol) in CH2Cl2 was added benzoylisocyanate
(1.24 mmol). The resulting reaction mixture was stirred at 55°C for 2 h. After completion of
reaction (monitored by TLC), the solvent was evaporated. The residue was re-dissolved in
MeOH (4 mL), and NaOMe (2.07 mmole) was added and refluxed for 4 h. The solvent was
evaporated and the crude material was purified by flash chromatography using
CH2Cl2:MeOH as an eluent. For compounds 8x and 8y, after reaction with
benzoylisocyanate (1st step), the solvent was evaporated, ethylenediamine (2 mL) was
added and stirred at 70 °C for 12 h.
furo[2,3-c]quinolin-4-amine (8a)
Solid (16 mg, 68%). 1H NMR (500 MHz, CDCl3) δ 7.93 (ddd, J = 8.0, 1.5, 0.5 Hz, 1H),
7.81 (ddd, J = 8.4, 1.1, 0.5 Hz, 1H), 7.79 (d, J = 2.0 Hz, 1H), 7.55 (ddd, J = 8.5, 7.0, 1.5 Hz,
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1H), 7.38 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 7.20 (d, J = 2.0 Hz, 1H), 5.16 (s, 2H). 13C NMR
(126 MHz, CDCl3) δ 146.4, 145.2, 144.3, 139.5, 129.9, 127.8, 126.6, 123.4, 123.1, 120.5,
106.2. HRMS (ESI) calculated for C11H8N2O, m/z : 184.0637, found 185.0704 (M+H)+.
2-methylfuro[2,3-c]quinolin-4-amine (8b)
Solid (35 mg, 70%). 1H NMR (500 MHz, CDCl3) δ 7.85 (ddd, J = 8.9, 5.0, 0.8 Hz, 2H),
7.55 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 7.36 (ddd, J = 8.1, 7.1, 1.2 Hz, 1H), 6.81 (d, J = 1.0 Hz,
1H), 5.88 (s, 2H), 2.57 (d, J = 1.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 158.3, 144.9,
138.3, 132.0, 131.3, 129.7, 128.0, 125.3, 123.5, 123.1, 102.7, 14.5. HRMS (ESI) calculated
for C12H10N2O, m/z : 198.0793, found 199.0859 (M+H)+.
2-propylfuro[2,3-c]quinolin-4-amine (8c)
Solid (38 mg, 78%). 1H NMR (500 MHz, CDCl3) δ 7.88 (dd, J = 8.0, 1.2 Hz, 1H), 7.81 –
7.76 (m, 1H), 7.52 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 7.34 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 6.81
(t, J = 0.8 Hz, 1H), 5.12 (s, 2H), 2.89 – 2.81 (m, 2H), 1.88 – 1.80 (m, 2H), 1.05 (t, J = 7.4
Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 161.7, 144.8, 144.1, 138.6, 131.4, 127.6, 126.5,
123.4, 122.8, 120.4, 101.8, 30.7, 21.3, 13.9. HRMS (ESI) calculated for C14H14N2O, m/z :
226.1106, found 227.1183 (M+H)+.
2-butylfuro[2,3-c]quinolin-4-amine (8d)
Solid (39 mg, 80%). 1H NMR (500 MHz, CDCl3) δ 7.87 (ddd, J = 8.0, 1.4, 0.4 Hz, 1H),
7.80 – 7.76 (m, 1H), 7.52 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 7.34 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H),
6.80 (t, J = 0.8 Hz, 1H), 5.11 (s, 2H), 2.90 – 2.83 (m, 2H), 1.79 (ddd, J = 13.3, 8.5, 6.7 Hz,
2H), 1.51 – 1.40 (m, 2H), 0.98 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 161.9,
144.8, 144.1, 138.6, 131.3, 127.6, 126.5, 123.4, 122.8, 120.4, 101.7, 30.0, 28.4, 22.4, 13.9.
HRMS (ESI) calculated for C15H16N2O, m/z : 240.1263, found 241.1349 (M+H)+.
2-pentylfuro[2,3-c]quinolin-4-amine (8e)
Solid (34 mg, 69%). 1H NMR (500 MHz, CDCl3) δ 7.88 (dd, J = 8.0, 1.1 Hz, 1H), 7.78 (dd,
J = 8.4, 0.5 Hz, 1H), 7.52 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 7.34 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H),
6.80 (s, 1H), 5.09 (s, 2H), 2.88 – 2.83 (m, 2H), 1.84 – 1.77 (m, 2H), 1.46 – 1.34 (m, 4H),
0.93 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 161.9, 144.8, 144.2, 138.6, 131.3,
127.6, 126.5, 123.4, 122.8, 120.4, 101.7, 31.5, 28.7, 27.6, 22.5, 14.1. HRMS (ESI)
calculated for C16H18N2O, m/z : 254.1419, found 255.1496 (M+H)+.
2-hexylfuro[2,3-c]quinolin-4-amine (8f)
Yellow solid (60 mg 67%). 1H NMR (500 MHz, CDCl3) δ 7.90 – 7.86 (m, 1H), 7.79 (dd, J =
8.4, 0.5 Hz, 1H), 7.52 (ddd, J = 8.5, 7.0, 1.5 Hz, 1H), 7.34 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H),
6.80 (s, 1H), 5.21 (s, 2H), 2.86 (t, 2H), 1.84 – 1.76 (m, 2H), 1.47 – 1.39 (m, 2H), 1.38 – 1.29
(m, 4H), 0.91 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 161.8, 144.8, 138.4, 131.2,
128.6, 127.5, 126.2, 123.3, 122.7, 120.2, 101.5, 31.5, 28.9, 28.6, 27.8, 22.6, 14.1. HRMS
(ESI) calculated for C17H20N2O, m/z : 268.1576, found 269.1658 (M+H)+.
2-isobutylfuro[2,3-c]quinolin-4-amine (8g)
Solid (55 mg, 70%). 1H NMR (500 MHz, CDCl3) δ 7.87 (ddd, J = 7.9, 1.4, 0.4 Hz, 1H),
7.80 (ddd, J = 8.5, 1.1, 0.5 Hz, 1H), 7.53 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 7.34 (ddd, J = 8.1,
7.0, 1.2 Hz, 1H), 6.81 (s, 1H), 5.36 (s, 2H), 2.73 (dd, J = 7.1, 0.6 Hz, 2H), 2.15 (dp, J = 13.6,
6.8 Hz, 1H), 1.02 (d, J = 6.7 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 161.1, 144.9, 143.8,
138.6, 131.4, 127.6, 126.2, 123.4, 122.8, 120.2, 102.7, 37.9, 28.0, 22.6. HRMS (ESI)
calculated for C15H16N2O, m/z : 240.1263, found 241.1337 (M+H)+.
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1H NMR (500 MHz, CDCl3) δ 7.89 (ddd, J = 8.0, 1.5, 0.5 Hz, 1H), 7.79 (dd, J = 8.4, 0.5 Hz,
1H), 7.53 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 7.35 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 6.80 (s, 1H),
5.27 (s, 2H), 1.45 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 169.8, 144.8, 143.6, 138.4, 131.3,
127.7, 126.1, 123.4, 123.0, 120.4, 99.0, 33.6, 29.2. HRMS (ESI) calculated for C15H16N2O,
m/z : 240.1263, found 241.1342 (M+H)+.
2-isopentylfuro[2,3-c]quinolin-4-amine (8i)
Solid (35 mg, 70%). 1H NMR (500 MHz, CDCl3) δ 7.87 (dd, J = 8.0, 1.0 Hz, 1H), 7.79 (dd,
J = 8.4, 0.5 Hz, 1H), 7.53 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 7.35 (ddd, J = 8.1, 7.1, 1.2 Hz, 1H),
6.81 (d, J = 0.8 Hz, 1H), 5.45 – 5.18 (m, 2H), 2.87 (t, 2H), 1.73 – 1.64 (m, 3H), 0.99 (d, J =
6.4 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 162.5, 144.8, 138.3, 131.6, 128.8, 127.8, 126.0,
123.4, 123.0, 120.2, 101.6, 36.8, 27.8, 26.7, 22.5. HRMS (ESI) calculated for C16H18N2O,
m/z : 254.1419, found 255.1496 (M+H)+.
2-cyclopropylfuro[2,3-c]quinolin-4-amine (8j)
Solid (28 mg, 74%). 1H NMR (500 MHz, CDCl3) δ 7.85 (dd, J = 8.0, 1.1 Hz, 1H), 7.77 (dd,
J = 8.4, 0.5 Hz, 1H), 7.52 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 7.33 (ddd, J = 8.1, 7.0, 1.1 Hz, 1H),
6.78 – 6.75 (m, 1H), 5.15 – 5.03 (m, 2H), 2.14 (tt, J = 8.4, 5.1 Hz, 1H), 1.10 (tdd, J = 11.1,
7.0, 4.3 Hz, 2H), 1.05 – 0.99 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 162.7, 144.5, 143.9,
137.9, 131.5, 127.5, 126.3, 123.3, 122.7, 120.1, 99.9, 29.7, 9.6, 8.0. HRMS (ESI) calculated
for C14H12N2O, m/z : 224.0950, found 225.1016 (M+H)+.
2-cyclopentylfuro[2,3-c]quinolin-4-amine (8k)
Solid (40 mg, 68%). 1H NMR (500 MHz, CDCl3) δ 7.87 (dd, J = 8.0, 1.1 Hz, 1H), 7.78 (dd,
J = 8.4, 0.5 Hz, 1H), 7.52 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 7.34 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H),
6.81 (d, J = 0.9 Hz, 1H), 5.13 (s, 2H), 3.35 – 3.27 (m, 1H), 2.20 – 2.11 (m, 2H), 1.89 – 1.82
(m, 3H), 1.79 – 1.70 (m, 3H). 13C NMR (126 MHz, CDCl3) δ 165.5, 144.8, 144.0, 138.5,
131.3, 127.6, 126.4, 123.4, 122.8, 120.4, 100.2, 39.3, 32.1, 29.9, 25.5. HRMS (ESI)
calculated for C16H16N2O, m/z : 252.1263, found 253.1338 (M+H)+.
2-(cyclopentylmethyl)furo[2,3-c]quinolin-4-amine (8l)
Solid (44 mg, 75%). 1H NMR (500 MHz, CDCl3) δ 7.88 (ddd, J = 7.9, 1.4, 0.4 Hz, 1H),
7.78 (dd, J = 8.4, 0.6 Hz, 1H), 7.52 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 7.34 (ddd, J = 8.1, 7.0,
1.2 Hz, 1H), 6.81 (s, 1H), 5.09 (s, 2H), 2.88 – 2.83 (m, 2H), 2.40 – 2.29 (m, 1H), 1.90 – 1.82
(m, 2H), 1.69 (qdd, J = 7.1, 6.7, 4.7 Hz, 2H), 1.64 – 1.54 (m, 2H), 1.36 – 1.26 (m, 2H). 13C
NMR (126 MHz, CDCl3) δ 161.6, 144.8, 144.1, 138.6, 131.3, 127.6, 126.5, 123.4, 122.8,
120.4, 102.1, 38.9, 34.8, 32.7, 25.2. HRMS (ESI) calculated for C17H18N2O, m/z :
266.1419, found 267.1495 (M+H)+.
2-(cyclohexylmethyl)furo[2,3-c]quinolin-4-amine (8m)
White solid (75 mg, 71%). 1H NMR (500 MHz, CDCl3) δ 7.89 – 7.86 (m, 1H), 7.78 (dd, J =
8.4, 0.5 Hz, 1H), 7.52 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 7.34 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H),
6.79 (s, 1H), 5.19 (s, 2H), 2.74 (d, J = 6.6 Hz, 2H), 1.81 – 1.65 (m, 6H), 1.32 – 1.14 (m, 4H),
1.04 (qd, J = 12.9, 2.8 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 160.8, 144.9, 144.1, 138.6,
131.3, 127.6, 126.4, 123.4, 122.8, 120.4, 102.7, 37.4, 36.6, 33.3, 26.4, 26.3. HRMS (ESI)
calculated for C18H20N2O, m/z : 280.1576, found 281.1656 (M+H)+.
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Solid (30 mg, 75%). 1H NMR (500 MHz, CDCl3) δ 7.97 (ddd, J = 8.0, 1.4, 0.4 Hz, 1H),
7.94 – 7.90 (m, 2H), 7.83 – 7.79 (m, 1H), 7.56 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 7.53 – 7.48
(m, 2H), 7.45 – 7.41 (m, 2H), 7.39 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 5.23 (s, 2H). 13C NMR
(126 MHz, CDCl3) δ 157.8, 145.0, 144.4, 139.0, 131.7, 129.9, 129.5, 129.1, 127.9, 126.7,
125.3, 123.4, 123.1, 120.3, 100.8. HRMS (ESI) calculated for C17H12N2O, m/z : 260.0950,
found 261.1023 (M+H)+.
2-benzylfuro[2,3-c]quinolin-4-amine (8o)
Solid (45 mg, 65%).1H NMR (500 MHz, CDCl3) δ 7.86 – 7.82 (m, 1H), 7.77 (dd, J = 8.4,
0.6 Hz, 1H), 7.52 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 7.40 – 7.35 (m, 2H), 7.35 – 7.28 (m, 4H),
6.79 (t, J = 0.9 Hz, 1H), 5.10 (s, 2H), 4.21 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 159.8,
144.9, 144.2, 139.0, 136.7, 131.2, 129.1, 129.0, 127.7, 127.2, 126.5, 123.4, 122.9, 120.4,
103.2, 35.2. HRMS (ESI) calculated for C18H14N2O, m/z : 274.1106, found 275.1182 (M
+H)+.
(4-aminofuro[2,3-c]quinolin-2-yl)methanol (8p)
White solid (12 mg, 67%). 1H NMR (500 MHz, DMSO) δ 8.00 (dd, J = 7.9, 1.2 Hz, 1H),
7.59 (d, J = 7.9 Hz, 1H), 7.45 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 7.31 (s, 1H), 7.25 (ddd, J = 8.0,
7.0, 1.1 Hz, 1H), 6.78 (s, 2H), 4.67 (s, 2H). 13C NMR (126 MHz, DMSO) δ 159.9, 146.1,
144.4, 138.6, 129.6, 127.1, 125.5, 123.5, 121.5, 119.4, 103.0, 56.4. HRMS (ESI) calculated
for C12H10N2O2, m/z : 214.0742, found 215.0805 (M+H)+.
2-(4-aminofuro[2,3-c]quinolin-2-yl)ethanol (8q)
White solid (20 mg, 65%). 1H NMR (500 MHz, CDCl3) δ 7.72 (d, J = 8.3 Hz, 1H), 7.65 (dd,
J = 8.0, 1.1 Hz, 1H), 7.50 (ddd, J = 8.4, 5.9, 1.5 Hz, 1H), 7.30 – 7.26 (m, 1H), 6.79 (s, 1H),
5.28 (s, 2H), 4.10 (t, J = 6.0 Hz, 2H), 3.11 (t, J = 5.8 Hz, 2H). 13C NMR (126 MHz, CDCl3)
δ 158.9, 144.6, 143.0, 138.3, 131.3, 127.8, 125.7, 123.4, 123.0, 119.8, 103.6, 60.5, 32.5.
HRMS (ESI) calculated for C13H12N2O2, m/z : 228.0899, found 229.0962 (M+H)+.
3-(4-aminofuro[2,3-c]quinolin-2-yl)propan-1-ol (8r)
Solid (70 mg, 75%). 1H NMR (500 MHz, CDCl3) δ 7.86 (dd, J = 8.0, 1.3 Hz, 1H), 7.78 (d, J
= 8.3 Hz, 1H), 7.52 (ddd, J = 8.4, 7.1, 1.5 Hz, 1H), 7.37 – 7.32 (m, 1H), 6.84 (s, 1H), 5.24
(s, 2H), 3.78 (t, J = 6.2 Hz, 2H), 3.00 (t, J = 7.5 Hz, 2H), 2.12 – 2.03 (m, 2H). 13C NMR
(126 MHz, CDCl3) δ 161.1, 144.8, 143.8, 138.6, 131.4, 127.8, 126.2, 123.4, 123.0, 120.2,
102.1, 61.8, 30.8, 25.1. HRMS (ESI) calculated for C14H14N2O2, m/z : 242.1055, found
243.1120 (M+H)+.
4-(4-aminofuro[2,3-c]quinolin-2-yl)butan-1-ol (8s)
Solid (28 mg, 70%). 1H NMR (500 MHz, MeOD) δ 7.95 – 7.91 (m, 1H), 7.65 (dd, J = 8.4,
0.5 Hz, 1H), 7.49 (ddd, J = 8.5, 7.0, 1.5 Hz, 1H), 7.31 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 7.01
(s, 1H), 3.63 (t, J = 6.5 Hz, 2H), 2.94 (t, J = 7.5 Hz, 2H), 1.95 – 1.87 (m, 2H), 1.70 – 1.63
(m, 2H). 13C NMR (126 MHz, MeOD) δ 163.9, 147.2, 144.2, 139.5, 133.0, 128.8, 125.5,
124.6, 123.7, 120.8, 102.8, 62.5, 33.0, 29.1, 25.3. HRMS (ESI) calculated for C15H16N2O2,
m/z : 256.1212, found 257.1282 (M+H)+.
2-(4-aminofuro[2,3-c]quinolin-2-yl)propan-2-ol (8t)
Solid (46 mg, 76%). 1H NMR (500 MHz, CDCl3) δ 7.77 – 7.71 (m, 2H), 7.52 – 7.47 (m,
1H), 7.29 (ddd, J = 8.1, 7.1, 1.0 Hz, 1H), 6.86 (s, 1H), 1.72 (s, 6H). 13C NMR (126 MHz,
CDCl3) δ 165.5, 145.1, 143.3, 138.4, 130.8, 127.9, 125.8, 123.3, 123.1, 120.0, 100.3, 77.2,
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69.2, 29.0. HRMS (ESI) calculated for C14H14N2O2, m/z : 242.1055, found 243.1123 (M
+H)+.
1-(4-aminofuro[2,3-c]quinolin-2-yl)-3-methylbutan-1-ol (8u)
Solid (35 mg, 77%). 1H NMR (500 MHz, MeOD) δ 8.00 (d, 1H), 7.67 (d, J = 8.2 Hz, 1H),
7.53 (ddd, J = 8.4, 7.1, 1.4 Hz, 1H), 7.39 – 7.33 (m, 1H), 7.24 (d, J = 2.6 Hz, 1H), 4.96 (t, J
= 6.7 Hz, 1H), 1.92 – 1.80 (m, 3H), 1.02 (dd, J = 6.2, 4.0 Hz, 6H). 13C NMR (126 MHz,
MeOD) δ 165.7, 147.3, 143.5, 132.8, 130.6, 129.2, 125.0, 124.7, 124.1, 120.6, 102.9, 66.9,
45.8, 25.7, 23.6, 22.3. HRMS MS (ESI) calculated for C16H18N2O2, m/z : 270.1368, found
271.1468 (M+H)+.
1-(4-aminofuro[2,3-c]quinolin-2-yl)propan-2-ol (8v)
Solid (30 mg, 73%). 1H NMR (500 MHz, MeOD) δ 7.96 (dd, J = 8.2, 1.3 Hz, 1H), 7.65 (dd,
J = 8.4, 0.4 Hz, 1H), 7.50 (ddd, J = 8.5, 7.1, 1.5 Hz, 1H), 7.33 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H),
7.10 (s, 1H), 4.29 – 4.22 (m, 1H), 3.05 – 3.01 (m, 2H), 1.30 (d, J = 6.2 Hz, 3H). 13C NMR
(126 MHz, MeOD) δ 161.3, 147.2, 144.0, 133.0, 130.4, 128.9, 125.3, 124.6, 123.8, 120.7,
104.4, 67.2, 39.0, 23.4. HRMS (ESI) calculated for C14H14N2O2, m/z : 242.1055, found
243.1121 (M+H)+.
2-(2-ethoxyethyl)furo[2,3-c]quinolin-4-amine (8w)
Solid (15 mg, 71%). 1H NMR (500 MHz, MeOD) δ 8.01 (ddd, J = 8.0, 2.3, 1.2 Hz, 1H),
7.68 (d, J = 8.2 Hz, 1H), 7.57 (t, J = 7.3 Hz, 1H), 7.45 – 7.38 (m, 1H), 7.16 (s, 1H), 3.89 (t, J
= 6.4 Hz, 2H), 3.58 (q, J = 7.0 Hz, 2H), 3.20 (dt, J = 6.5, 3.1 Hz, 2H), 1.20 (t, J = 7.0 Hz,
3H). 13C NMR (126 MHz, MeOD) δ 163.1, 146.51, 134.2, 133.1, 130.6, 129.7, 129.2,
125.0, 124.7, 123.3, 104.2, 68.9, 67.4, 30.3, 15.4. HRMS (ESI) calculated for C15H16N2O2,
m/z : 256.1212, found 257.1280 (M+H)+.
2-(aminomethyl)furo[2,3-c]quinolin-4-amine (8x)
Solid (24 mg, 65%). 1H NMR (500 MHz, MeOD) δ 7.93 (dd, J = 8.0, 1.1 Hz, 1H), 7.65 (dd,
J = 8.4, 0.4 Hz, 1H), 7.49 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 7.31 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H),
7.15 (s, 1H), 4.03 (s, 2H). 13C NMR (126 MHz, MeOD) δ 162.7, 147.6, 145.0, 140.0, 132.4,
128.7, 126.0, 124.5, 123.6, 121.0, 102.9, 39.8. HRMS (ESI) calculated for C12H11N3O, m/
z : 213.0902, found 214.0967 (M+H)+.
2-(2-aminoethyl)furo[2,3-c]quinolin-4-amine (8y)
Solid (25 mg, 66%). 1H NMR (500 MHz, MeOD) δ 7.94 (dd, J = 8.0, 1.1 Hz, 1H), 7.64 (dd,
J = 8.4, 0.5 Hz, 1H), 7.48 (ddd, J = 8.5, 7.0, 1.5 Hz, 1H), 7.30 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H),
7.07 (s, 1H), 3.14 – 3.02 (m, 4H). 13C NMR (126 MHz, MeOD) δ 161.1, 147.4, 145.0,
140.0, 132.6, 128.6, 126.0, 124.5, 123.5, 120.9, 103.7, 40.9, 32.7. HRMS (ESI) calculated
for C13H13N3O, m/z : 227.1059, found 228.1121 (M+H)+.
Compound 10 was synthesized similarly as compound 5
3-iodoquinolin-4-ol (10)—Solid (1.6g). 1H NMR (500 MHz, DMSO) δ 11.19 (s, 1H),
8.50 (s, 1H), 7.98 – 7.85 (m, 2H), 7.65 – 7.60 (m, 1H), 7.60 – 7.55 (m, 1H). 13C NMR (126
MHz, DMSO) δ 152.2, 142.6, 141.3, 130.9, 129.9, 129.2, 128.5, 126.6, 94.5. MS (ESI)
calculated for C9H6INO, m/z : 270.95, found 271.96 (M+H)+.
Compounds 11a–11c were synthesized similarly as compound 6c
2-propylfuro[3,2-c]quinoline (11a)—Solid (55 mg, 71%). 1H NMR (500 MHz, CDCl3)
δ 9.10 (s, 1H), 8.28 – 8.23 (m, 1H), 8.19 (dd, J = 8.0, 0.8 Hz, 1H), 7.67 (ddd, J = 8.5, 6.9, 1.6
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Hz, 1H), 7.61 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 6.60 (t, J = 0.9 Hz, 1H), 2.91 – 2.86 (m, 2H),
1.90 – 1.81 (m, 2H), 1.06 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 160.1, 155.1,
145.4, 145.2, 129.8, 127.8, 126.8, 121.6, 119.9, 117.3, 101.4, 30.5, 21.3, 13.9. MS (ESI)
calculated for C14H13NO, m/z : 211.10, found 212.11 (M+H)+.
2-butylfuro[3,2-c]quinoline (11b)—Solid (258 mg, 69%). 1H NMR (500 MHz, CDCl3)
δ 9.13 (s, 1H), 8.25 (dd, J = 7.9, 1.6 Hz, 2H), 7.68 – 7.59 (m, 2H), 6.59 (t, J = 0.8 Hz, 1H),
2.94 – 2.87 (m, 2H), 1.81 (ddd, J = 15.2, 8.4, 6.7 Hz, 2H), 1.53 – 1.42 (m, 2H), 0.99 (t, J =
7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 160.5, 155.1, 145.4, 145.3, 129.9, 127.9, 126.8,
121.7, 119.9, 117.3, 101.3, 30.0, 28.3, 22.4, 13.9. MS (ESI) calculated for C15H15NO, m/z :
225.11, found 226.13 (M+H)+.
2-phenylfuro[3,2-c]quinoline (11c)—Solid (68 mg, 75%). 1H NMR (500 MHz, CDCl3)
δ 9.18 (s, 1H), 8.38 (dd, J = 8.1, 1.2 Hz, 1H), 8.22 (d, J = 8.1 Hz, 1H), 7.98 – 7.93 (m, 2H),
7.74 – 7.64 (m, 2H), 7.51 (t, J = 7.7 Hz, 2H), 7.44 – 7.39 (m, 1H), 7.21 (s, 1H). 13C NMR
(126 MHz, CDCl3) δ 156.6, 155.3, 145.9, 145.5, 130.0, 129.9, 129.1, 129.1, 128.3, 127.1,
125.1, 122.05, 120.1, 117.3, 100.6. MS (ESI) calculated for C17H11NO, m/z : 245.10, found
246.09 (M+H)+.
Compounds 12a–12c were synthesized similarly as compound 7b
2-propylfuro[3,2-c]quinoline 5-oxide (12a)—Solid (88 mg, 82%). 1H NMR (500
MHz, CDCl3) δ 8.87 – 8.82 (m, 1H), 8.79 (s, 1H), 8.25 – 8.20 (m, 1H), 7.76 – 7.70 (m, 2H),
6.51 (t, J = 0.9 Hz, 1H), 2.89 – 2.83 (m, 2H), 1.89 – 1.80 (m, 2H), 1.06 (t, J = 7.4 Hz,
3H). 13C NMR (126 MHz, CDCl3) δ 162.2, 147.4, 138.7, 130.7, 129.1, 128.8, 121.3, 120.9,
120.6, 117.9, 101.2, 30.5, 21.2, 13.9. MS (ESI) calculated for C14H13NO2, m/z : 227.10,
found 228.10 (M+H)+.
2-butylfuro[3,2-c]quinoline 5-oxide (12b)—Yellow solid (100 mg, 79%). 1H NMR
(500 MHz, CDCl3) δ 8.88 – 8.82 (m, 1H), 8.79 (s, 1H), 8.26 – 8.20 (m, 1H), 7.76 – 7.70 (m,
2H), 6.51 (t, J = 0.9 Hz, 1H), 2.91 – 2.85 (m, 2H), 1.83 – 1.76 (m, 2H), 1.51 – 1.43 (m, 2H),
0.99 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 162.4, 147.4, 138.7, 130.7, 129.1,
128.8, 121.3, 121.0, 120.6, 117.9, 101.1, 29.9, 28.3, 22.4, 13.9. MS (ESI) calculated for
C15H15NO2, m/z : 241.11, found 242.12 (M+H)+.
2-phenylfuro[3,2-c]quinoline 5-oxide (12c)—Solid (90 mg, 85%). 1H NMR (500
MHz, CDCl3) δ 8.90 – 8.86 (m, 2H), 8.37 – 8.33 (m, 1H), 7.94 – 7.90 (m, 2H), 7.78 (dd, J =
6.5, 3.3 Hz, 2H), 7.54 – 7.49 (m, 2H), 7.46 – 7.41 (m, 1H), 7.11 (s, 1H). 13C NMR (126
MHz, CDCl3) δ 158.4, 147.6, 139.3, 130.7, 129.7, 129.4, 129.2, 129.2, 125.2, 121.4, 121.4,
120.8, 118.1, 100.0. MS (ESI) calculated for C17H11NO2, m/z : 261.10, found 262.09 (M
+H)+.
Compounds 13a–13c were synthesized similarly as compound 8a
2-propylfuro[3,2-c]quinolin-4-amine (13a)—Solid (35 mg, 71%). 1H NMR (500 MHz,
CDCl3) δ 8.05 (dd, 1H), 7.76 (d, J = 8.2 Hz, 1H), 7.52 (ddd, J = 8.5, 7.0, 1.5 Hz, 1H), 7.34
(ddd, J = 8.1, 7.0, 1.1 Hz, 1H), 6.40 (t, J = 0.9 Hz, 1H), 5.10 (s, 2H), 2.86 – 2.81 (m, 2H),
1.87 – 1.78 (m, 2H), 1.04 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 159.1, 156.1,
151.9, 145.0, 128.2, 126.1, 122.9, 119.8, 114.7, 111.0, 99.7, 30.5, 21.4, 13.9. HRMS (ESI)
calculated for C14H14N2O, m/z : 226.1106, found 227.1177 (M+H)+.
2-butylfuro[3,2-c]quinolin-4-amine (13b)—White solid (55 mg 69%). 1H NMR (500
MHz, CDCl3) δ 8.05 (ddd, J = 8.0, 1.5, 0.5 Hz, 1H), 7.79 – 7.73 (m, 1H), 7.52 (ddd, J = 8.5,
7.0, 1.5 Hz, 1H), 7.34 (ddd, J = 8.1, 7.0, 1.1 Hz, 1H), 6.39 (t, J = 0.9 Hz, 1H), 5.14 (s, 2H),
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2.89 – 2.83 (m, 2H), 1.77 (ddd, J = 13.3, 8.5, 6.6 Hz, 2H), 1.50 – 1.41 (m, 2H), 0.98 (t, J =
7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 159.3, 156.0, 151.9, 144.9, 128.3, 126.0, 123.0,
119.8, 114.7, 111.0, 99.6, 30.1, 28.2, 22.4, 13.9. HRMS (ESI) calculated for C15H16N2O, m/
z : 240.1263, found 241.1340 (M+H)+.
2-phenylfuro[3,2-c]quinolin-4-amine (13c)—Solid (33 mg, 67%). 1H NMR (500
MHz, MeOD) δ 8.93 (ddd, J = 8.0, 1.4, 0.4 Hz, 1H), 8.73 (dd, J = 8.4, 1.2 Hz, 2H), 8.47 –
8.44 (m, 1H), 8.35 – 8.31 (m, 1H), 8.31 – 8.27 (m, 2H), 8.21 – 8.12 (m, 3H). 13C NMR (126
MHz, MeOD) δ 156.9, 156.5, 154.3, 145.9, 130.9, 129.7, 129.5, 129.4, 125.5, 125.6, 123.5,
120.6, 114.9, 112.9, 100.7, 49.0. HRMS (ESI) calculated for C17H12N2O, m/z : 260.0950,
found 261.1027 (M+H)+.
Compound 15 was synthesized similarly as compound 5
4-iodoisoquinolin-3-ol (15)—Solid (1.4g). 1H NMR (500 MHz, DMSO) δ 8.84 (s, 1H),
7.94 (d, J = 8.2 Hz, 1H), 7.76 (dd, J = 8.5, 0.6 Hz, 1H), 7.73 – 7.67 (m, 1H), 7.37 (ddd, J =
7.9, 6.8, 0.9 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 159.8, 149.4, 140.9, 132.8, 128.8,
128.5, 123.8, 123.5. MS (ESI) calculated for C9H6INO, m/z : 270.95, found 271.96 (M+H)+.
Compound 16 was synthesized similarly as compound 6c
2-butylfuro[2,3-c]isoquinoline (16)—Solid (68 mg, 81%). 1H NMR (500 MHz, CDCl3)
δ 8.87 (s, 1H), 8.06 (dd, J = 8.5, 0.8 Hz, 2H), 7.74 (ddd, J = 8.4, 6.9, 1.2 Hz, 1H), 7.57 –
7.52 (m, 1H), 6.85 (t, J = 0.9 Hz, 1H), 2.93 – 2.87 (m, 2H), 1.82 (ddd, J = 13.3, 8.5, 6.7 Hz,
2H), 1.46 (dq, J = 14.8, 7.4 Hz, 2H), 0.98 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)
δ 158.6, 158.3, 146.3, 131.3, 130.2, 128.8, 126.4, 125.2, 123.0, 114.4, 100.5, 29.9, 28.6,
22.4, 14.0. MS (ESI) calculated for C15H15NO, m/z : 225.12, found 226.12 (M+H)+.
Compound 17 was synthesized similarly as compound 7b
2-butylfuro[2,3-c]isoquinoline 4-oxide (17)—Solid (20 mg, 74%). 1H NMR (500
MHz, MeOD) δ 8.94 (s, 1H), 8.24 (dd, J = 8.3, 0.9 Hz, 1H), 8.08 (d, J = 8.4 Hz, 1H), 7.83
(ddd, J = 8.3, 7.0, 1.2 Hz, 1H), 7.70 (ddd, J = 8.2, 7.0, 1.1 Hz, 1H), 7.30 (t, J = 0.9 Hz, 1H),
3.03 – 2.97 (m, 2H), 1.90 – 1.83 (m, 2H), 1.54 – 1.46 (m, 2H), 1.02 (t, J = 7.4 Hz, 3H). 13C
NMR (126 MHz, MeOD) δ 162.3, 134.6, 134.6, 131.8, 131.1, 130.5, 128.9, 128.1, 124.2,
121.7, 103.5, 30.8, 28.9, 23.3, 14.1. MS (ESI) calculated for C15H15NO2, m/z : 241.11,
found 242.11 (M+H)+.
Compound 18 was synthesized similarly as compound 8a
2-butylfuro[2,3-c]isoquinolin-5-amine (18)—Solid (15 mg, 62%). 1H NMR (500
MHz, MeOD) δ 8.17 – 8.13 (m, 1H), 7.96 (ddd, J = 8.2, 1.1, 0.7 Hz, 1H), 7.69 (ddd, J = 8.2,
6.9, 1.1 Hz, 1H), 7.43 (ddd, J = 8.3, 6.9, 1.2 Hz, 1H), 6.74 (t, J = 0.9 Hz, 1H), 2.82 – 2.75
(m, 2H), 1.79 – 1.71 (m, 2H), 1.51 – 1.41 (m, 2H), 0.99 (t, J = 7.4 Hz, 3H). 13C NMR (126
MHz, MeOD) δ 158.0, 156.0, 154.4, 134.4, 131.7, 125.9, 124.9, 124.1, 117.0, 106.1, 101.2,
31.3, 29.0, 23.3, 14.2. HRMS (ESI) calculated for C15H16N2O, m/z : 240.1263, found
241.1350 (M+H)+.
1-bromo-2-butylfuro[2,3-c]quinoline (19)—To a stirred solution of 2-butylfuro[2,3-
c]quinoline 7d (100 mg, 0.44 mmol) in CH2Cl2 was added bromine (80 µL, 1.55 mmol) and
stirred at room temperature for 6 h. After completion of reaction (monitored by TLC), the
solvent was evaporated, the crude material was purified by flash chromatography using
CH2Cl2:MeOH to furnish 19 as yellow solid (50 mg, 75%). 1H NMR (500 MHz, CDCl3) δ
9.08 (s, 1H), 8.90 (d, J = 8.0 Hz, 1H), 8.22 (d, J = 8.3 Hz, 1H), 7.71 (ddd, J = 8.4, 7.0, 1.5
Hz, 1H), 7.68 – 7.63 (m, 1H), 2.98 – 2.92 (m, 2H), 1.84 – 1.76 (m, 2H), 1.44 (dq, J = 14.8,
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7.4 Hz, 2H), 0.98 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 159.4, 147.4, 144.5,
136.2, 130.1, 127.9, 127.7, 126.8, 122.9, 122.3, 94.0, 29.6, 26.6, 22.4, 13.9. MS (ESI)
calculated for C15H14BrNO, m/z : 303.03, found 304.04 (M+H)+.
Compound 21 was synthesized similarly as compound 8a
1-bromo-2-butylfuro[2,3-c]quinolin-4-amine (21)—Solid (21 mg, 72%). 1H NMR
(500 MHz, MeOD) δ 8.67 (ddd, J = 8.2, 1.4, 0.5 Hz, 1H), 7.68 (ddd, J = 8.4, 1.1, 0.5 Hz,
1H), 7.53 (ddd, J = 8.5, 7.0, 1.5 Hz, 1H), 7.35 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 2.97 (t, J = 7.5
Hz, 2H), 1.86 – 1.78 (m, 2H), 1.50 – 1.41 (m, 2H), 1.00 (t, J = 7.4 Hz, 3H). 13C NMR (126
MHz, MeOD) δ 159.7, 147.2, 145.3, 138.9, 129.1, 128.5, 126.3, 123.4, 123.1, 120.4, 95.0,
30.7, 27.2, 23.3, 14.1. HRMS (ESI) calculated for C15H15BrN2O, m/z : 318.0368, found
319.0429 (M+H)+.
1-benzyl-2-butylfuro[2,3-c]quinoline (22)—To a stirred solution of 19 (50 mg, 0.164
mmol) in 1,4-dioxane were added 2-benzyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (54 mg,
0.246 mmol), Pd(dppf)Cl2 (8 mg, 0.009 mmol), Cs2CO3 (160 mg, 0.492 mmol) and 0.1 ml
of water. The resulting reaction mixture was stirred at 70°C under nitrogen atmosphere for
12 h. After completion of reaction (monitored by TLC), the reaction mixture was diluted
with water and extracted with ethylacetate (3 × 10 mL). The combined organic layer was
dried over Na2SO4 and concentrated under reduced pressure, crude material was purified by
flash chromatography using CH2Cl2:MeOH as an eluent to obtain 22 (24 mg, 92%). 1H
NMR (500 MHz, CDCl3) δ 9.11 (d, J = 5.7 Hz, 1H), 8.19 – 8.14 (m, 1H), 7.94 (dd, J = 8.3,
0.8 Hz, 1H), 7.61 – 7.54 (m, 1H), 7.44 – 7.37 (m, 1H), 7.28 – 7.24 (m, 3H), 7.19 (dd, J =
10.3, 4.3 Hz, 2H), 4.38 (s, 2H), 2.91 – 2.86 (m, 2H), 1.80 – 1.72 (m, 2H), 1.44 – 1.35 (m,
2H), 0.93 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 159.8, 148.3, 144.7, 138.9,
136.5, 136.3, 130.3, 130.1, 128.9, 128.0, 127.4, 126.9, 126.6, 126.5, 123.6, 113.9, 101.0,
30.6, 30.5, 26.4, 22.6, 13.9. MS (ESI) calculated for C22H21NO, m/z : 315.20, found 316.18
(M+H)+.
Compound 24 was synthesized similarly as compound 8a
1-benzyl-2-butylfuro[2,3-c]quinolin-4-amine (24)—Solid (31 mg, 75%). 1H NMR
(500 MHz, CDCl3) δ 7.79 – 7.73 (m, 2H), 7.44 (ddd, J = 8.4, 7.0, 1.4 Hz, 1H), 7.30 – 7.23
(m, 3H), 7.23 – 7.18 (m, 2H), 7.15 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 5.09 (s, 2H), 4.33 (s, 2H),
2.87 – 2.81 (m, 2H), 1.73 (ddd, J = 13.0, 8.5, 6.7 Hz, 2H), 1.39 (dq, J = 14.7, 7.4 Hz, 2H),
0.92 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 158.4, 144.9, 144.4, 139.1, 138.2,
130.0, 128.8, 128.0 (2C), 127.2 (2C), 126.6, 126.6, 123.4, 122.8, 121.0, 114.7, 30.7, 30.4,
26.3, 22.6, 13.9. HRMS (ESI) calculated for C22H22N2O, m/z : 330.1732, found 331.1808
(M+H)+.
Compounds 27a–b were synthesized similarly as compound 7b
2-propylfuro[2,3-c]pyridine 6-oxide (27a)—Oil (85 mg, 78%). 1H NMR (500 MHz,
CDCl3) δ 8.48 (s, 1H), 8.08 (dd, J = 6.7, 1.5 Hz, 1H), 7.30 (d, J = 6.7 Hz, 1H), 6.41 (d, J =
0.8 Hz, 1H), 2.75 (t, J = 7.5 Hz, 2H), 1.81 – 1.72 (m, 2H), 1.00 (t, J = 7.4 Hz, 3H). 13C
NMR (126 MHz, CDCl3) δ 165.3, 152.0, 135.0, 128.5, 124.7, 115.8, 102.0, 30.5, 20.8, 13.8.
MS (ESI) calculated for C10H11NO2, m/z : 177.08, found 178.08 (M+H)+.
2-butylfuro[2,3-c]pyridine 6-oxide (27b)—Oil (80 mg, 73%). 1H NMR (500 MHz,
CDCl3) δ 8.52 – 8.47 (m, 1H), 8.10 (dd, J = 6.7, 1.5 Hz, 1H), 7.31 (d, J = 6.7 Hz, 1H), 6.42
(d, J = 0.9 Hz, 1H), 2.79 (t, 2H), 1.78 – 1.67 (m, 2H), 1.48 – 1.37 (m, 2H), 0.96 (t, J = 7.4
Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 165.5, 152.0, 135.1, 128.4, 124.8, 115.8, 101.9,
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29.5, 28.3, 22.4, 13.9. MS (ESI) calculated for C11H13NO2, m/z : 191.09, found 192.10 (M
+H)+.
Compounds 28a–b was synthesized similarly as compound 8a
2-propylfuro[2,3-c]pyridin-7-amine (28a)—Oil (33 mg, 67%). 1H NMR (500 MHz,
CDCl3) δ 7.80 (d, J = 5.5 Hz, 1H), 6.85 (d, J = 5.5 Hz, 1H), 6.34 (t, J = 0.8 Hz, 1H), 4.67 (s,
2H), 2.79 – 2.71 (m, 2H), 1.82 – 1.74 (m, 2H), 1.01 (t, J = 7.4 Hz, 3H). 13C NMR (126
MHz, CDCl3) δ 161.8, 144.1, 140.5, 139.2, 135.3, 107.5, 102.4, 30.6, 21.1, 13.9. HRMS
(ESI) calculated for C10H12N2O, m/z : 176.0950, found 177.1067 (M+H)+.
2-butylfuro[2,3-c]pyridin-7-amine (28b)—Oil (35 mg, 71%). 1H NMR (500 MHz,
CDCl3) δ 7.80 (d, J = 5.5 Hz, 1H), 6.85 (d, J = 5.5 Hz, 1H), 6.33 (t, J = 0.8 Hz, 1H), 4.68 (s,
2H), 2.80 – 2.74 (m, 2H), 1.77 – 1.69 (m, 2H), 1.47 – 1.38 (m, 2H), 0.96 (t, J = 7.4 Hz,
3H). 13C NMR (126 MHz, CDCl3) δ 162.0, 144.0, 140.4, 139.2, 135.3, 107.5, 102.3, 29.8,
28.3, 22.4, 13.9. HRMS (ESI) calculated for C11H14N2O, m/z: 190.1106, found 191.1231
(M+H)+.
Human TLR2/–3/–4/–5/–7/–8/–9 Reporter Gene assays (NF-κB induction)
The induction of NF-κB was quantified using human TLR2/–3/–4/–5/–7/–8/–9-specific
HEK-Blue™ reporter gene assays as previously described by us.17,22,23 HEK293 cells
stably co-transfected with the appropriate hTLR, MD2, and secreted alkaline phosphatase
(sAP), were maintained in HEK-Blue™ Selection medium containing zeocin and normocin.
Stable expression of secreted alkaline phosphatase (sAP) under control of NF-κB/AP-1
promoters is inducible by appropriate TLR agonists, and extracellular sAP in the supernatant
is proportional to NF-κB induction. HEK-Blue™ cells were incubated at a density of ~105
cells/ml in a volume of 80 µl/well, in 384-well, flat-bottomed, cell culture-treated microtiter
plates until confluency was achieved, and subsequently stimulated with graded
concentrations of stimuli. sAP was assayed spectrophotometrically using an alkaline
phosphatase-specific chromogen (present in HEK-detection medium as supplied by the
vendor) at 620 nm.
Immunoassays for cytokines
Fresh human peripheral blood mononuclear cells (hPBMC) were isolated from human blood
obtained by venipuncture with informed consent and as per institutional guidelines on
Ficoll-Hypaque gradients as described elsewhere.59 Aliquots of PBMCs (105 cells in 100
µL/well) were stimulated for 12 h with graded concentrations of test compounds.
Supernatants were isolated by centrifugation, and were assayed in triplicates using analyte-
specific multiplexed cytokine/chemokine bead array assays as reported by us previously.60
PBMC supernatants were also analyzed for 41 chemokines and cytokines (EGF, Eotaxin,
FGF-2, Flt-3 ligand, Fractalkine, G-CSF, GM-CSF, GRO, IFN-α2, IFN-γ, IL-10, IL-12
(p40), IL-12 (p70), IL-13, IL-15, IL-17, IL-1ra, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6,
IL-7, IL-8, IL-9, IP-10, MCP-1, MCP-3, MDC (CCL22), MIP-1α, MIP-1β, PDGF-AA,
PDGF-AB/BB, RANTES, TGFα, TNF-α, TNF-β, VEGF, sCD40L) using a magnetic bead-
based multiplexed assay kit (Milliplex MAP Human Cytokine/Chemokine kit). Data were
acquired and processed on a MAGPIX instrument (EMD Millipore, Billerica, MA) with an
intra-assay coefficients of variation ranging from 4–8% for the 41 analytes.
Flow-cytometric immunostimulation experiments
CD69 upregulation was determined by flow cytometry using protocols published by us
previously.17,18 Briefly, heparin-anticoagulated whole blood samples were obtained by
venipuncture from healthy human volunteers with informed consent and as per guidelines
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approved by the University of Kansas Human Subjects Experimentation Committee.
Aliquots of whole human blood samples were stimulated with graded concentrations of
either 8d or 2 (used as a reference compound) in a 6-well polystyrene plate and incubated at
37°C in a rotary (100 rpm) incubator for 16.5 h. Negative (endotoxin free water) controls
were included in each experiment. Following incubation, 200 µL aliquots of anticoagulated
whole blood were stained with 20 µL of fluorochrome-conjugated antibodies at 37°C in the
dark for 30 min. For triple color flow cytometry experiments, CD3-PE, CD56-APC, CD69-
PE-Cy7 were used to analyze CD69 activation of each of the main peripheral blood
lymphocyte populations: natural killer lymphocytes (NK cells: CD3−CD56+), cytokine-
induced killer phenotype (CIK cells: CD3+CD56+), nominal B lymphocytes (CD3−CD56−),
and nominal T lymphocytes (CD3+CD56−). Following staining, erythrocytes were lysed and
leukocytes fixed in one step by mixing 200 µL of the samples in 4 mL pre-warmed Whole
Blood Lyse/Fix Buffer (Becton-Dickinson Biosciences, San Jose, CA). After washing the
cells twice at 200 g for 8 minutes in saline, the cells were transferred to a 96-well plate.
Flow cytometry was performed using a BD FACSArray instrument in the tri-color mode
(tri-color flow experiment) and two-color mode (two-color flow experiment) for acquisition
on 100,000 gated events. Post-acquisition analyses were performed using FlowJo v 7.0
software (Treestar, Ashland, OR). Compensation for spillover was computed for each
experiment on singly-stained samples.
Transcriptomal profiling in human PBMCs
Detailed procedures for transcriptomal profiling have been described by us previously.17
Briefly, fresh human PBMC samples were stimulated with 10 µg/mL of 8d and 2 for two
hours, and total RNA was extracted from treated and negative control blood samples with
QIAamp RNA Blood Mini Kit (Qiagen). Subsequently, 160 ng of each of the RNA samples
was used. The Human Genome GeneChip U133 plus 2.0 oligonucleotide array (Affymetrix,
Santa Clara, CA) was employed. Established standard protocols at the KU Genomics
Facility were performed on cRNA target preparation, array hybridization, washing, staining
and image scanning. The microarray data was first subjected to quality assessment using the
Affymetrix GeneChip Operating Software (GCOS). QC criteria included low background,
low noise, detection of positive controls, and a 5’/3’ ratio of < 3.0. To facilitate direct
comparison of gene expression data between different samples, the GeneChip data were first
subjected to preprocessing. This step involved scaling (in GCOS) data from all chips to a
target intensity value of 500, and further normalizations steps in GeneSpring GX (Agilent
Technologies, Santa Clara, CA). Prior to identifying target genes, genes that were detected
as non-expressed in all samples, i.e., those with absence calls, were filtered out. To identify
genes whose expression was changed by our compounds, a fold change threshold of 2.0
between the compound treatment and the negative control was used.
Molecular modeling and induced fit docking
We used quantum mechanics/molecular mechanics (QM/MM) methods61,62 for induced fit
docking by calculating quantum mechanical charges for the ligand, while the
macromolecule was handled using conventional molecular mechanics force fields. Correct
bond orders were assigned, hydrogen atoms were added to the residues, and formal partial
charges were assigned to atoms using OPLS-all atom force field.63 The docking grid was
generated using co-crystallized ligand as grid center. Ligands were modeled in Schrödinger
molecular modeling software (Schrödinger, New York, NY) and were minimized to a
gradient of 0.001KCal/MolÅ2. The QM charges for ligands were obtained from Jaguar
(Schrödinger), using the 3–21G basis set with the BLYP density functional theory.64 Initial
docking was performed with Glide65,66 using 0.5 van der Waals (vdW) radius scaling factor
for both ligand and protein. This soft docking procedure was applied to generate diverse
docking solutions and top 20 poses for each ligand were retained. Finally, each ligand was
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re-docked into its corresponding structures and the resulting complexes were ranked
according to GlideScore.65,66
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Abbreviations
APCs antigen-presenting cells
CD69 cluster of differentiation 69
DCs dendritic cells
EC50 Half-maximal effective concentration
ESI-TOF Electrospray ionization-time of flight
G-CSF granulocyte colony-stimulating factor
GRO growth-related oncogene
HEK Human embryonic kidney
Ig immunoglobulin
IFN interferon
MPL monophosphoryl lipid A
MIP macrophage inflammatory protein
MHC Major histocompatibility complex
NK Natural killer
NF-κB Nuclear factor-κB
NOD nucleotide oligomerization domain
sAP Secreted alkaline phosphatase
SAR Structure activity relationship
TNF-α Tumor necrosis factor-α
Th1 Helper T lymphocyte, type 1
Th2 Helper T lymphocyte, type 2
Tregs T-regulatory cells
TGF transforming growth factor
TLR Toll like receptor
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Representative TLR8/7 dual-agonistic heterocyclic small molecules.
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Dose-response profiles of human TLR8 (Panel A) and human TLR7 (Panel B) agonism by
select C2-alkyl furo[2,3-c]quinolines. Error bars represent standard deviations obtained on
quadruplicates. Dual TLR7/8-agonistic compounds 1 and 2 were used as comparators. C.
Potency of TLR8 agonism (EC50 values) of a homologous series of C2-alkyl analogues.
Compound 8a was inactive.
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Proinflammatory cytokine induction profiles of 8d in human blood. 2 was used as reference/
comparator compound. Means of duplicate values of a representative experiment is shown.
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Dose-response profiles of IL-12p40 and IL-18 induction and the absence of IFN-α by 8d. 2
was used as reference/comparator compound. Means of duplicate values of a representative
experiment is shown.
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Absence of CD69 upregulation in human natural killer cells by 8d. Inset: gating on
lymphocytes showing CD3+CD56− (T cells, Quadrant A), CD3−CD56− (nominal B cells,
Quadrant B), CD3−CD56+ (cytokine-induced killer cells, Quadrant C), and CD3−CD56+
(natural killer cells, Quadrant D).
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Disparate responses in select analytes (out of 41 analytes) in human PBMCs. G-CSF, GRO,
MIP-1α, and MIP-1β are induced by 8d (and 2, data not shown), but not by a pure TLR7
agonistic imidazoquinoline. Dose responses represent percent maximal response (G-CSF:
622 pg/mL, GRO: 515 pg/mL, MIP-1α: 10780 pg/mL, and MIP-1β: 10374 pg/mL). Means
of duplicate values of a representative experiment is shown. Analytes were below detection
limits for negative controls (medium alone), and are not shown for clarity.
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Induced fit docking of ligands in human TLR8 (PDB ID: 3W3K). A. Both 2 and 8d occupy
the same binding pocket. B. The binding modes of the TLR7/8-dual active imidazoquinoline
CL097 and 8d are superimposable. C–F. Binding site interactions of 2, 8d, 13b, and 18,
respectively.
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Syntheses of C2-alkylfuro[2,3-c]quinoline analogues. Reagents: (i) I2, KI, NaOH; (ii)
Pd(PPh3)4, CuI alkyne, Et3N:CH3CN (1:3); (iii) m-CPBA, CHCl3; (iv) (a) benzoyl
isocyanate, CH2Cl2, (b) NaOCH3, MeOH.
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Syntheses of C2-alkylfuro[3,2-c]quinoline analogues. Reagents: (i) I2, KI, NaOH; (ii)
Pd(PPh3)4 CuI alkyne, Et3N:CH3CN (1:3); (iii) m-CPBA, CHCl3; (iv) (a) benzoyl
isocyanate, CH2Cl2, (b) NaOCH3, MeOH.
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Syntheses of C2-alkylfuro[2,3-c]isoquinoline analogues. Reagents: (i) I2, KI, NaOH; (ii)
Pd(PPh3)4, CuI alkyne, Et3N:CH3CN (1:3); (iii) m-CPBA, CHCl3; (iv) (a) benzoyl
isocyanate, CH2Cl2, (b) NaOCH3, MeOH.
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Syntheses of C1- substituted furo[2,3-c]quinoline analogues. Reagents: (i) Br2, CH2Cl2; (ii)
m-CPBA CHCl3; (iii) (a) benzoyl isocyanate, CH2Cl2, (b) NaOCH3, MeOH; (iv)
Pd(dppf)Cl2, 2-benzyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, Cs2CO3 1,4-Dioxane
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Syntheses of C2-alkylfuro[2,3-c]pyridine analogues. Reagents: (i) Pd(PPh3)4, CuI alkyne,
Et3N:CH3CN (1:3); (ii) m-CPBA, CHCl3; (iii) (a) benzoyl isocyanate, CH2Cl2, (b)
NaOCH3, MeOH.
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Table 1
Transcriptomal profiling of 8d in human PBMCs






208375_at IFNA1 interferon, alpha 1 7.38297 0.5418
IFNA1 ///
208344_x_at IFNA13 interferon, alpha 1///13 5.36195 0.85859
208261_x_at IFNA10 interferon, alpha 10 5.87577 0.7771
211405_x_at IFNA17 interferon, alpha 17 4.25712 0.81187
211145_x_at IFNA21 interferon, alpha 21 4.96822 0.58271
214569_at IFNA5 interferon, alpha 5 7.03922 1.22985
208259_x_at IFNA7 interferon, alpha 7 5.77059 0.80266
207932_at IFNA8 interferon, alpha 8 4.18566 0.61895
210354_at IFNG interferon, gamma 5.60123 4.54852
204470_at CXCL1 chemokine (C-X-C motif) ligand 1 0.88813 1.99629
209774_x_at CXCL2 chemokine (C-X-C motif) ligand 2 2.83012 2.8543
207850_at CXCL3 chemokine (C-X-C motif) ligand 3 1.47026 1.75638
215101_s_at CXCL5 chemokine (C-X-C motif) ligand 5 1.51721 2.39582
203915_at CXCL9 chemokine (C-X-C motif) ligand 9 1.88404 0.81365
204533_at CXCL10 chemokine (C-X-C motif) ligand 10 7.689 6.42653
210163_at CXCL11 chemokine (C-X-C motif) ligand 11 8.89003 6.50285
211122_s_at CXCL11 chemokine (C-X-C motif) ligand 11 9.00636 6.56354
210118_s_at IL1A interleukin 1, alpha 4.67389 4.82369
205067_at IL1B interleukin 1, beta 2.45708 2.44858
216243_s_at IL1RN interleukin 1 receptor antagonist 3.97769 3.66761
207538_at IL4 interleukin 4 2.20255 2.24232
205207_at IL6 interleukin 6 7.85102 7.67767
interleukin 12B (natural killer cell
207901_at IL12B stimulatory factor 2) 5.84181 3.26706
207844_at IL13 interleukin 13 1.57695 2.04086
205992_s_at IL15 interleukin 15 1.16516 1.06962
209827_s_at IL16 interleukin 16 -1.7103 -0.64723
206295_at IL18 interleukin 18 2.64035 2.40756
207072_at IL18RAP interleukin 18 receptor accessory protein 1.12674 0.51353
224071_at IL20 interleukin 20 0.31683 0.81046
222974_at IL22 interleukin 22 2.16422 0.38534
220054_at IL23A interleukin 23, alpha subunit p19 4.73191 4.96526
206569_at IL24 interleukin 24 -0.6150 -0.00233
205926_at IL27RA interleukin 27 receptor, alpha 0.20872 0.16269
1552915_at IL28A interleukin 28A (interferon, lambda 2) 1.65564 0.59624
interleukin 28 receptor, alpha (interferon,
244261_at IL28RA Lambda receptor) 1.13284 0.78929
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1552917_at IL29 interleukin 29 (interferon, lambda 1) 1.02924 0.76252
203828_s_at IL32 interleukin 32 0.35684 0.70521
207113_s_at TNF tumor necrosis factor 3.81754 3.3126
tumor necrosis factor, alpha-induced
206025_s_at TNFAIP6 Protein 6 4.28297 4.17629
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